kw1	kw2	iteration	R1C1	pg	inv_edge_weight	edge_weight	crit_p
abdominal pain/chemically induced	antineoplastic agents immunological/therapeutic use	0	1	0.0005888664151666	0.830190299122522	0.032258064516129	0.0013888221509739
abdominal pain/chemically induced	disease progression	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
abdominal pain/chemically induced	enterocolitis/chemically induced	0	1	9.620737539961509e-11	0.830190299122522	0.021505376344086	1.0197981792359201e-09
abdominal pain/chemically induced	gastritis/complications	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
abdominal pain/chemically induced	glucocorticoids/therapeutic use	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
abdominal pain/chemically induced	neoplasms/drug therapy	0	1	0.0046517769353922	0.830190299122522	0.129032258064516	0.008650672897396
antineoplastic agents immunological/therapeutic use	disease progression	0	1	0.0005888664151666	0.830190299122522	0.032258064516129	0.0013888221509739
antineoplastic agents immunological/therapeutic use	enterocolitis/chemically induced	0	1	0.0031884016641496	0.830190299122522	0.0638148667601683	0.0061761120560381
antineoplastic agents immunological/therapeutic use	gastritis/complications	0	1	0.0005888664151666	0.830190299122522	0.032258064516129	0.0013888221509739
antineoplastic agents immunological/therapeutic use	glucocorticoids/therapeutic use	0	1	0.0005888664151666	0.830190299122522	0.032258064516129	0.0013888221509739
disease progression	enterocolitis/chemically induced	0	1	9.620737539961509e-11	0.830190299122522	0.021505376344086	1.0197981792359201e-09
disease progression	gastritis/complications	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
disease progression	glucocorticoids/therapeutic use	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
disease progression	neoplasms/drug therapy	0	1	0.0046517769353922	0.830190299122522	0.129032258064516	0.008650672897396
enterocolitis/chemically induced	colitis ulcerative/physiopathology	0	1	0.0	0.830190299122522	0.021505376344086	0.0
enterocolitis/chemically induced	crohn disease/physiopathology	0	1	0.0	0.830190299122522	0.021505376344086	0.0
enterocolitis/chemically induced	gastritis/complications	0	1	9.620737539961509e-11	0.830190299122522	0.021505376344086	1.0197981792359201e-09
enterocolitis/chemically induced	glucocorticoids/therapeutic use	0	1	9.620737539961509e-11	0.830190299122522	0.021505376344086	1.0197981792359201e-09
gastritis/complications	glucocorticoids/therapeutic use	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
gastritis/complications	neoplasms/drug therapy	0	1	0.0046517769353922	0.830190299122522	0.129032258064516	0.008650672897396
glucocorticoids/therapeutic use	neoplasms/drug therapy	0	1	0.0046517769353922	0.830190299122522	0.129032258064516	0.008650672897396
neoplasms/drug therapy	AHR	0	1	0.0001112700446812	0.830190299122522	0.129032258064516	0.0003281348458297
neoplasms/drug therapy	anti-bacterial agents/adverse effects	0	1	0.0012043173595439	0.830190299122522	0.129032258064516	0.0026891839170452
neoplasms/drug therapy	biological products/therapeutic use	0	1	0.0001112700446812	0.830190299122522	0.129032258064516	0.0003281348458297
neoplasms/drug therapy	biomarkers/analysis	0	1	0.0004436759846442	0.830190299122522	0.129032258064516	0.0010715617451913
neoplasms/drug therapy	butyrates/metabolism	0	1	4.86148063361114e-07	0.830190299122522	0.129032258064516	3.07142551289074e-06
neoplasms/drug therapy	chemical and drug induced liver injury/diagnosis	0	1	4.86148063361114e-07	0.830190299122522	0.129032258064516	3.07142551289074e-06
neoplasms/drug therapy	clostridium infections/chemically induced	0	1	0.0012043173595439	0.830190299122522	0.129032258064516	0.0026891839170452
neoplasms/drug therapy	colitis/chemically induced	0	11	0.0017136073625698	5.36975220686589e-05	0.126233984373546	0.0037111950599129
neoplasms/drug therapy	colon/immunology	0	2	1.6323991047784102e-09	0.584635003932401	0.0154277699859747	1.25589414996662e-08
neoplasms/drug therapy	diarrhea/chemically induced	0	5	6.95203111253928e-05	0.0777468263617441	0.0161314791677859	0.0002516978247196
neoplasms/drug therapy	escherichia coli infections/drug therapy	0	1	0.0012043173595439	0.830190299122522	0.129032258064516	0.0026891839170452
neoplasms/drug therapy	feces/chemistry	0	1	0.0004436759846442	0.830190299122522	0.129032258064516	0.0010715617451913
neoplasms/drug therapy	hepatitis/diagnosis	0	1	4.86148063361114e-07	0.830190299122522	0.129032258064516	3.07142551289074e-06
neoplasms/drug therapy	immune checkpoint inhibitors/adverse effects	0	11	7.30735188636533e-05	5.36975220686589e-05	0.0079594183628137	0.0002635619546159
neoplasms/drug therapy	intestinal mucosa/immunology	0	1	1.4296142507475e-05	0.830190299122522	0.129032258064516	5.4994032065045e-05
neoplasms/drug therapy	leukocyte l1 antigen complex/analysis	0	1	0.0004436759846442	0.830190299122522	0.129032258064516	0.0010715617451913
neoplasms/drug therapy	protein kinase inhibitors/therapeutic use	0	1	0.0012043173595439	0.830190299122522	0.129032258064516	0.0026891839170452
neoplasms/drug therapy	t-lymphocyte subsets/immunology	0	1	1.4296142507475e-05	0.830190299122522	0.129032258064516	5.4994032065045e-05
neoplasms/drug therapy	tryptophan/pharmacology	0	1	0.0001112700446812	0.830190299122522	0.129032258064516	0.0003281348458297
neoplasms/drug therapy	virus diseases/etiology	0	1	0.0012043173595439	0.830190299122522	0.129032258064516	0.0026891839170452
ACAD8	carcinoma non-small-cell lung/complications	0	1	2.89640156303506e-09	0.830190299122522	0.021505376344086	2.14198999312825e-08
ACAD8	colon/drug effects	0	1	0.0033230272463853	0.830190299122522	0.0638148667601683	0.0063786076318945
ACAD8	CRP	0	1	2.89640156303506e-09	0.830190299122522	0.021505376344086	2.14198999312825e-08
ACAD8	drug-related side effects and adverse reactions	0	1	3.63207168585511e-06	0.830190299122522	0.0427769985974754	2.07484813671004e-05
ACAD8	immune checkpoint inhibitors/pharmacology	0	1	0.0007650097159677	0.830190299122522	0.0846189808321645	0.001771405992799
ACAD8	infliximab/administration & dosage	0	1	2.89640156303506e-09	0.830190299122522	0.021505376344086	2.14198999312825e-08
ACAD8	melanoma/complications	0	1	0.0005782582526319	0.830190299122522	0.0638148667601683	0.0013705798087225
ACAD8	mesalamine/pharmacology	0	1	2.89640156303506e-09	0.830190299122522	0.021505376344086	2.14198999312825e-08
ACAD8	protective agents/pharmacology	0	1	2.89640156303506e-09	0.830190299122522	0.021505376344086	2.14198999312825e-08
ACAD8	trinitrobenzenesulfonic acid/adverse effects	0	1	2.89640156303506e-09	0.830190299122522	0.021505376344086	2.14198999312825e-08
ACAD8	urothelium/drug effects	0	1	2.89640156303506e-09	0.830190299122522	0.021505376344086	2.14198999312825e-08
carcinoma non-small-cell lung/complications	CRP	0	1	0.0	0.830190299122522	0.010752688172043	0.0
carcinoma non-small-cell lung/complications	drug-related side effects and adverse reactions	0	1	4.16946477344027e-11	0.830190299122522	0.021505376344086	4.59846172700811e-10
carcinoma non-small-cell lung/complications	immune checkpoint inhibitors/administration & dosage	0	1	0.000872653019809	0.830190299122522	0.043010752688172	0.0020084704002361
carcinoma non-small-cell lung/complications	infliximab/administration & dosage	0	1	0.0	0.830190299122522	0.010752688172043	0.0
carcinoma non-small-cell lung/complications	melanoma/complications	0	1	8.11373358056144e-07	0.830190299122522	0.032258064516129	4.85297920743299e-06
carcinoma non-small-cell lung/complications	urothelium/drug effects	0	1	0.0	0.830190299122522	0.010752688172043	0.0
colon/drug effects	cd8-positive t-lymphocytes/drug effects	0	2	1.42285160453781e-06	0.584635003932401	0.0007012622720897	8.30214330721145e-06
colon/drug effects	colitis ulcerative/immunology	0	2	1.42285160453781e-06	0.584635003932401	0.0007012622720897	8.30214330721145e-06
colon/drug effects	crohn disease/immunology	0	1	0.0001660054582111	0.830190299122522	0.032258064516129	0.0004664777824253
colon/drug effects	graft vs host disease/immunology	0	1	0.0001660054582111	0.830190299122522	0.032258064516129	0.0004664777824253
colon/drug effects	immunologic memory/drug effects	0	1	0.0010372325214909	0.830190299122522	0.032258064516129	0.0023588076889209
colon/drug effects	interferon-gamma/metabolism	0	1	0.0010372325214909	0.830190299122522	0.032258064516129	0.0023588076889209
colon/drug effects	macrophages/drug effects	0	1	0.0001660054582111	0.830190299122522	0.032258064516129	0.0004664777824253
colon/drug effects	mesalamine/pharmacology	0	1	2.34397230222116e-05	0.830190299122522	0.032258064516129	8.71793207141907e-05
colon/drug effects	phenotype	0	2	1.42285160453781e-06	0.584635003932401	0.0007012622720897	8.30214330721145e-06
colon/drug effects	protective agents/pharmacology	0	1	2.34397230222116e-05	0.830190299122522	0.032258064516129	8.71793207141907e-05
colon/drug effects	trinitrobenzenesulfonic acid/adverse effects	0	1	2.34397230222116e-05	0.830190299122522	0.032258064516129	8.71793207141907e-05
colon/drug effects	CD4	1	1	0.0044756364491657	0.8192464059779487	0.063143445435827	0.0080231092761845
colon/drug effects	CD68	1	1	0.0044756364491657	0.8192464059779487	0.063143445435827	0.0080231092761845
CRP	drug-related side effects and adverse reactions	0	1	4.16946477344027e-11	0.830190299122522	0.021505376344086	4.59846172700811e-10
CRP	immune checkpoint inhibitors/administration & dosage	0	1	0.000872653019809	0.830190299122522	0.043010752688172	0.0020084704002361
CRP	infliximab/administration & dosage	0	1	0.0	0.830190299122522	0.010752688172043	0.0
CRP	melanoma/complications	0	1	8.11373358056144e-07	0.830190299122522	0.032258064516129	4.85297920743299e-06
CRP	urothelium/drug effects	0	1	0.0	0.830190299122522	0.010752688172043	0.0
drug-related side effects and adverse reactions	infliximab/administration & dosage	0	1	4.16946477344027e-11	0.830190299122522	0.021505376344086	4.59846172700811e-10
drug-related side effects and adverse reactions	infliximab/adverse effects	0	1	0.0001746066731989	0.830190299122522	0.0846189808321645	0.0004899257830345
drug-related side effects and adverse reactions	melanoma/complications	0	1	0.000124270133592	0.830190299122522	0.0638148667601683	0.0003619960532727
drug-related side effects and adverse reactions	melanoma/drug therapy	0	1	0.0010372325214909	0.830190299122522	0.105189340813464	0.0023588076889209
drug-related side effects and adverse reactions	TNF	0	1	0.000124270133592	0.830190299122522	0.0638148667601683	0.0003619960532727
drug-related side effects and adverse reactions	urothelium/drug effects	0	1	4.16946477344027e-11	0.830190299122522	0.021505376344086	4.59846172700811e-10
immune checkpoint inhibitors/pharmacology	AHR	0	1	8.488771907622091e-10	0.830190299122522	0.043010752688172	7.74320237197327e-09
immune checkpoint inhibitors/pharmacology	b7-h1 antigen/metabolism	0	1	2.36599509539914e-07	0.830190299122522	0.043010752688172	1.53548253129985e-06
immune checkpoint inhibitors/pharmacology	colitis collagenous/drug therapy	0	1	6.36879438076221e-12	0.830190299122522	0.043010752688172	9.068402745145001e-11
immune checkpoint inhibitors/pharmacology	colitis/diagnosis	0	1	4.23227637775803e-05	0.830190299122522	0.0846189808321645	0.0001541065520756
immune checkpoint inhibitors/pharmacology	gastrointestinal tract/metabolism	0	1	2.36599509539914e-07	0.830190299122522	0.043010752688172	1.53548253129985e-06
immune checkpoint inhibitors/pharmacology	IL22	0	1	0.0045271389450379	0.830190299122522	0.0846189808321645	0.0084684128501298
immune checkpoint inhibitors/pharmacology	inflammatory bowel diseases	0	1	9.10500023044714e-05	0.830190299122522	0.0846189808321645	0.0002777578837603
immune checkpoint inhibitors/pharmacology	mesalamine/pharmacology	0	1	1.3929446125438e-06	0.830190299122522	0.043010752688172	8.22829201465502e-06
immune checkpoint inhibitors/pharmacology	programmed cell death 1 receptor/metabolism	0	1	2.36599509539914e-07	0.830190299122522	0.043010752688172	1.53548253129985e-06
immune checkpoint inhibitors/pharmacology	protective agents/pharmacology	0	1	1.3929446125438e-06	0.830190299122522	0.043010752688172	8.22829201465502e-06
immune checkpoint inhibitors/pharmacology	skin neoplasms/complications	0	1	6.36879438076221e-12	0.830190299122522	0.043010752688172	9.068402745145001e-11
immune checkpoint inhibitors/pharmacology	trinitrobenzenesulfonic acid/adverse effects	0	1	1.3929446125438e-06	0.830190299122522	0.043010752688172	8.22829201465502e-06
immune checkpoint inhibitors/pharmacology	tryptophan/pharmacology	0	1	8.488771907622091e-10	0.830190299122522	0.043010752688172	7.74320237197327e-09
immune checkpoint inhibitors/pharmacology	melanoma/complications	1	1	0.0042474605028671	0.8192464059779487	0.1235713646265405	0.0076274818889516
infliximab/administration & dosage	immune checkpoint inhibitors/administration & dosage	0	1	0.000872653019809	0.830190299122522	0.043010752688172	0.0020084704002361
infliximab/administration & dosage	melanoma/complications	0	1	8.11373358056144e-07	0.830190299122522	0.032258064516129	4.85297920743299e-06
infliximab/administration & dosage	urothelium/drug effects	0	1	0.0	0.830190299122522	0.010752688172043	0.0
melanoma/complications	antibodies monoclonal/adverse effects	0	1	2.84150786487025e-05	0.830190299122522	0.032258064516129	0.0001046640348681
melanoma/complications	colitis collagenous/drug therapy	0	1	2.20490292690556e-12	0.830190299122522	0.032258064516129	3.2361190650275496e-11
melanoma/complications	lymphocytes/drug effects	0	1	2.84150786487025e-05	0.830190299122522	0.032258064516129	0.0001046640348681
melanoma/complications	neutrophils/drug effects	0	1	2.84150786487025e-05	0.830190299122522	0.032258064516129	0.0001046640348681
melanoma/complications	skin neoplasms/complications	0	1	2.20490292690556e-12	0.830190299122522	0.032258064516129	3.2361190650275496e-11
melanoma/complications	urothelium/drug effects	0	1	8.11373358056144e-07	0.830190299122522	0.032258064516129	4.85297920743299e-06
melanoma/complications	vitamin d/administration & dosage	0	1	2.84150786487025e-05	0.830190299122522	0.032258064516129	0.0001046640348681
mesalamine/pharmacology	protective agents/pharmacology	0	1	0.0	0.830190299122522	0.010752688172043	0.0
mesalamine/pharmacology	trinitrobenzenesulfonic acid/adverse effects	0	1	0.0	0.830190299122522	0.010752688172043	0.0
protective agents/pharmacology	trinitrobenzenesulfonic acid/adverse effects	0	1	0.0	0.830190299122522	0.010752688172043	0.0
urothelium/drug effects	immune checkpoint inhibitors/administration & dosage	0	1	0.000872653019809	0.830190299122522	0.043010752688172	0.0020084704002361
adenocarcinoma of lung/drug therapy	b7-h1 antigen/antagonists & inhibitors	0	1	8.488771907622091e-10	0.830190299122522	0.032258064516129	7.74320237197327e-09
adenocarcinoma of lung/drug therapy	biomarkers/metabolism	0	1	0.0	0.830190299122522	0.010752688172043	0.0
adenocarcinoma of lung/drug therapy	glycoproteins/metabolism	0	1	0.0	0.830190299122522	0.010752688172043	0.0
b7-h1 antigen/antagonists & inhibitors	biomarkers/metabolism	0	1	8.488771907622091e-10	0.830190299122522	0.032258064516129	7.74320237197327e-09
b7-h1 antigen/antagonists & inhibitors	CD274	0	3	0.0002239297954592	0.347909608055624	0.0035063113604488	0.0005814517869145
b7-h1 antigen/antagonists & inhibitors	colitis/epidemiology	0	1	8.488771907622091e-10	0.830190299122522	0.032258064516129	7.74320237197327e-09
b7-h1 antigen/antagonists & inhibitors	glycoproteins/metabolism	0	1	8.488771907622091e-10	0.830190299122522	0.032258064516129	7.74320237197327e-09
b7-h1 antigen/antagonists & inhibitors	neoplasms/complications	0	1	0.0007148389160953	0.830190299122522	0.0946781129109319	0.0016572450205467
b7-h1 antigen/antagonists & inhibitors	programmed cell death 1 receptor/antagonists & inhibitors	0	2	0.0023776856511018	0.584635003932401	0.0187722515913259	0.0047603611986383
biomarkers/metabolism	glycoproteins/metabolism	0	1	0.0	0.830190299122522	0.010752688172043	0.0
adrenal cortex hormones/therapeutic use	beclomethasone/adverse effects	0	1	1.2526646386845599e-12	0.830190299122522	0.032258064516129	1.8672532270391797e-11
adrenal cortex hormones/therapeutic use	biological products/therapeutic use	0	1	1.2526646386845599e-12	0.830190299122522	0.032258064516129	1.8672532270391797e-11
adrenal cortex hormones/therapeutic use	diarrhea/chemically induced	0	3	1.37004461520096e-06	0.347909608055624	0.002805049088359	8.16889101813573e-06
adrenal cortex hormones/therapeutic use	inflammation/drug therapy	0	1	0.0004982368131516	0.830190299122522	0.0638148667601683	0.0011838553418347
adrenal cortex hormones/therapeutic use	skin neoplasms/drug therapy	0	1	0.0002334339983105	0.830190299122522	0.0638148667601683	0.0005814517869145
adrenal cortex hormones/therapeutic use	SNCA	0	1	0.0009302340538402	0.830190299122522	0.0946781129109319	0.0021230700654632
adrenal cortex hormones/therapeutic use	TNF	0	1	0.0012219719371479	0.830190299122522	0.0946781129109319	0.0026891839170452
adrenal cortex hormones/therapeutic use	tumor necrosis factor inhibitors	0	1	2.25073886195304e-08	0.830190299122522	0.032258064516129	1.50681043810751e-07
adrenal cortex hormones/therapeutic use	antineoplastic agents/adverse effects	1	1	0.003954425372989	0.8192464059779487	0.0425531914893617	0.007113781094266
adrenal cortex hormones/therapeutic use	intestinal mucosa/chemistry	1	1	0.003954425372989	0.8192464059779487	0.0425531914893617	0.007113781094266
adrenal cortex hormones/therapeutic use	leukemia lymphocytic chronic b-cell/drug therapy	1	1	0.003954425372989	0.8192464059779487	0.0425531914893617	0.007113781094266
adrenal cortex hormones/therapeutic use	class i phosphatidylinositol 3-kinases/antagonists & inhibitors	1	1	0.003954425372989	0.8192464059779487	0.0425531914893617	0.007113781094266
adrenal cortex hormones/therapeutic use	purines/adverse effects	1	1	0.003954425372989	0.8192464059779487	0.0425531914893617	0.007113781094266
adrenal cortex hormones/therapeutic use	colon/chemistry	1	1	0.003954425372989	0.8192464059779487	0.0425531914893617	0.007113781094266
adrenal cortex hormones/therapeutic use	lymphocytosis/chemically induced	1	1	0.003954425372989	0.8192464059779487	0.0425531914893617	0.007113781094266
adrenal cortex hormones/therapeutic use	protein kinase inhibitors/adverse effects	1	1	0.003954425372989	0.8192464059779487	0.0425531914893617	0.007113781094266
adrenal cortex hormones/therapeutic use	apoptosis/drug effects	1	1	0.003954425372989	0.8192464059779487	0.0425531914893617	0.007113781094266
adrenal cortex hormones/therapeutic use	quinazolinones/adverse effects	1	1	0.003954425372989	0.8192464059779487	0.0425531914893617	0.007113781094266
adrenal cortex hormones/therapeutic use	lymphoma non-hodgkin/drug therapy	1	1	0.003954425372989	0.8192464059779487	0.0425531914893617	0.007113781094266
adrenal cortex hormones/therapeutic use	PIK3CD	1	1	0.003954425372989	0.8192464059779487	0.0425531914893617	0.007113781094266
beclomethasone/adverse effects	diarrhea/chemically induced	0	1	0.001239801514261	0.830190299122522	0.150537634408602	0.0027158912620093
beclomethasone/adverse effects	inflammation/drug therapy	0	1	1.69131375571396e-11	0.830190299122522	0.021505376344086	1.90948322242736e-10
beclomethasone/adverse effects	immune checkpoint inhibitors	1	1	0.004953734053108	0.8192464059779487	0.3191489361702128	0.0088335817030947
biological products/therapeutic use	diarrhea/chemically induced	0	1	0.001239801514261	0.830190299122522	0.150537634408602	0.0027158912620093
diarrhea/chemically induced	biomarkers/analysis	0	1	0.0033916470872356	0.830190299122522	0.150537634408602	0.0064907348469864
diarrhea/chemically induced	feces	0	1	0.001239801514261	0.830190299122522	0.150537634408602	0.0027158912620093
diarrhea/chemically induced	feces/chemistry	0	1	0.0033916470872356	0.830190299122522	0.150537634408602	0.0064907348469864
diarrhea/chemically induced	leukocyte l1 antigen complex/analysis	0	1	0.0033916470872356	0.830190299122522	0.150537634408602	0.0064907348469864
diarrhea/chemically induced	LTF	0	1	0.001239801514261	0.830190299122522	0.150537634408602	0.0027158912620093
inflammation/drug therapy	cd8-positive t-lymphocytes/cytology	0	1	0.0001276936833728	0.830190299122522	0.021505376344086	0.00036582514696
inflammation/drug therapy	chemokines/metabolism	0	1	0.0001276936833728	0.830190299122522	0.021505376344086	0.00036582514696
inflammation/drug therapy	colitis/drug therapy	0	1	0.0028052417422615	0.830190299122522	0.0638148667601683	0.005535058163635
inflammation/drug therapy	ctla-4 antigen/immunology	0	1	0.0001276936833728	0.830190299122522	0.021505376344086	0.00036582514696
inflammation/drug therapy	gene expression regulation/genetics	0	1	0.0001276936833728	0.830190299122522	0.021505376344086	0.00036582514696
inflammation/drug therapy	melanoma/genetics	0	1	0.0001276936833728	0.830190299122522	0.021505376344086	0.00036582514696
inflammation/drug therapy	multigene family	0	1	0.0001276936833728	0.830190299122522	0.021505376344086	0.00036582514696
inflammation/drug therapy	myeloid cells/cytology	0	1	0.0001276936833728	0.830190299122522	0.021505376344086	0.00036582514696
inflammation/drug therapy	receptors antigen t-cell/genetics	0	1	0.0001276936833728	0.830190299122522	0.021505376344086	0.00036582514696
inflammation/drug therapy	receptors cxcr3/genetics	0	1	0.0001276936833728	0.830190299122522	0.021505376344086	0.00036582514696
inflammation/drug therapy	receptors cxcr6/genetics	0	1	0.0001276936833728	0.830190299122522	0.021505376344086	0.00036582514696
inflammation/drug therapy	t-lymphocytes regulatory/cytology	0	1	0.0001276936833728	0.830190299122522	0.021505376344086	0.00036582514696
skin neoplasms/drug therapy	colon/diagnostic imaging	0	1	6.08395890666635e-07	0.830190299122522	0.021505376344086	3.69687694073866e-06
skin neoplasms/drug therapy	drug resistance/immunology	0	1	6.08395890666635e-07	0.830190299122522	0.021505376344086	3.69687694073866e-06
skin neoplasms/drug therapy	glucocorticoids/pharmacology	0	1	6.08395890666635e-07	0.830190299122522	0.021505376344086	3.69687694073866e-06
skin neoplasms/drug therapy	immunosuppressive agents/pharmacology	0	1	6.08395890666635e-07	0.830190299122522	0.021505376344086	3.69687694073866e-06
skin neoplasms/drug therapy	infliximab/adverse effects	0	1	0.0015703678212359	0.830190299122522	0.0846189808321645	0.0034087164993381
skin neoplasms/drug therapy	intestinal mucosa/diagnostic imaging	0	1	6.08395890666635e-07	0.830190299122522	0.021505376344086	3.69687694073866e-06
skin neoplasms/drug therapy	melanoma/drug therapy	0	2	3.54466825891464e-08	0.584635003932401	0.0023375409069658	2.36476469860459e-07
skin neoplasms/drug therapy	mucositis/chemically induced	0	1	6.08395890666635e-07	0.830190299122522	0.021505376344086	3.69687694073866e-06
skin neoplasms/drug therapy	SNCA	0	1	0.0009302340538402	0.830190299122522	0.0638148667601683	0.0021230700654632
skin neoplasms/drug therapy	TNF	0	1	0.0012219719371479	0.830190299122522	0.0638148667601683	0.0026891839170452
skin neoplasms/drug therapy	tumor necrosis factor inhibitors	0	1	2.25073886195304e-08	0.830190299122522	0.021505376344086	1.50681043810751e-07
SNCA	colitis ulcerative/chemically induced	0	1	2.03116920582946e-06	0.830190299122522	0.032258064516129	1.16731049539838e-05
SNCA	hashimoto disease/chemically induced	0	1	2.03116920582946e-06	0.830190299122522	0.032258064516129	1.16731049539838e-05
SNCA	paclitaxel/therapeutic use	0	1	2.03116920582946e-06	0.830190299122522	0.032258064516129	1.16731049539838e-05
SNCA	squamous cell carcinoma of head and neck/drug therapy	0	1	2.03116920582946e-06	0.830190299122522	0.032258064516129	1.16731049539838e-05
SNCA	TNF	0	1	0.0036748977609006	0.830190299122522	0.0946781129109319	0.0068877258622775
SNCA	tongue neoplasms/drug therapy	0	1	2.03116920582946e-06	0.830190299122522	0.032258064516129	1.16731049539838e-05
SNCA	tumor necrosis factor inhibitors	0	1	4.50371576143915e-07	0.830190299122522	0.032258064516129	2.87394303438993e-06
TNF	CXCL10	0	1	1.09558519411079e-05	0.830190299122522	0.032258064516129	4.30118631762015e-05
TNF	CXCL9	0	1	1.09558519411079e-05	0.830190299122522	0.032258064516129	4.30118631762015e-05
TNF	dermatitis	0	1	1.09558519411079e-05	0.830190299122522	0.032258064516129	4.30118631762015e-05
TNF	immune checkpoint inhibitors	0	3	0.0006526577599305	0.347909608055624	0.0312870859855432	0.0015167734542599
TNF	melanoma/drug therapy	0	2	1.42285160453781e-06	0.584635003932401	0.0068584991446141	8.30214330721145e-06
TNF	psoriasis	0	1	1.09558519411079e-05	0.830190299122522	0.032258064516129	4.30118631762015e-05
TNF	rna	0	1	1.09558519411079e-05	0.830190299122522	0.032258064516129	4.30118631762015e-05
TNF	TCIM	0	1	1.09558519411079e-05	0.830190299122522	0.032258064516129	4.30118631762015e-05
TNF	tumor necrosis factor inhibitors	0	1	8.11373358056144e-07	0.830190299122522	0.032258064516129	4.85297920743299e-06
TNF	infliximab/adverse effects	1	1	0.0042474605028671	0.8192464059779487	0.1235713646265405	0.0076274818889516
tumor necrosis factor inhibitors	melanoma/drug therapy	0	1	2.34397230222116e-05	0.830190299122522	0.053763440860215	8.71793207141907e-05
adrenal insufficiency/chemically induced	angiogenesis inhibitors/therapeutic use	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
adrenal insufficiency/chemically induced	axitinib/administration & dosage	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
adrenal insufficiency/chemically induced	bevacizumab/administration & dosage	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
adrenal insufficiency/chemically induced	carcinoma renal cell/drug therapy	0	1	0.0012219719371479	0.830190299122522	0.021505376344086	0.0026891839170452
adrenal insufficiency/chemically induced	diabetes mellitus type 1/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
adrenal insufficiency/chemically induced	exanthema/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
adrenal insufficiency/chemically induced	fatigue/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
adrenal insufficiency/chemically induced	hepatitis autoimmune/etiology	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
adrenal insufficiency/chemically induced	hypophysitis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
adrenal insufficiency/chemically induced	ipilimumab/therapeutic use	0	1	0.0036027646835737	0.830190299122522	0.032258064516129	0.0067591691408641
adrenal insufficiency/chemically induced	myasthenia gravis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
adrenal insufficiency/chemically induced	myocarditis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
adrenal insufficiency/chemically induced	nephritis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
adrenal insufficiency/chemically induced	nivolumab/therapeutic use	0	1	0.00299295859196	0.830190299122522	0.021505376344086	0.0058034197088005
adrenal insufficiency/chemically induced	pruritus/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
adrenal insufficiency/chemically induced	pneumonia/chemically induced	1	1	0.0052037117615472	0.8192464059779487	0.0319148936170212	0.0091356041252636
angiogenesis inhibitors/therapeutic use	axitinib/administration & dosage	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
angiogenesis inhibitors/therapeutic use	bevacizumab/administration & dosage	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
angiogenesis inhibitors/therapeutic use	carcinoma renal cell/drug therapy	0	1	0.0012219719371479	0.830190299122522	0.021505376344086	0.0026891839170452
angiogenesis inhibitors/therapeutic use	diabetes mellitus type 1/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
angiogenesis inhibitors/therapeutic use	exanthema/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
angiogenesis inhibitors/therapeutic use	fatigue/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
angiogenesis inhibitors/therapeutic use	hepatitis autoimmune/etiology	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
angiogenesis inhibitors/therapeutic use	hypophysitis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
angiogenesis inhibitors/therapeutic use	ipilimumab/therapeutic use	0	1	0.0036027646835737	0.830190299122522	0.032258064516129	0.0067591691408641
angiogenesis inhibitors/therapeutic use	myasthenia gravis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
angiogenesis inhibitors/therapeutic use	myocarditis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
angiogenesis inhibitors/therapeutic use	nephritis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
angiogenesis inhibitors/therapeutic use	nivolumab/therapeutic use	0	1	0.00299295859196	0.830190299122522	0.021505376344086	0.0058034197088005
angiogenesis inhibitors/therapeutic use	pruritus/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
angiogenesis inhibitors/therapeutic use	pneumonia/chemically induced	1	1	0.0052037117615472	0.8192464059779487	0.0319148936170212	0.0091356041252636
axitinib/administration & dosage	bevacizumab/administration & dosage	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
axitinib/administration & dosage	carcinoma renal cell/drug therapy	0	1	0.0012219719371479	0.830190299122522	0.021505376344086	0.0026891839170452
axitinib/administration & dosage	diabetes mellitus type 1/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
axitinib/administration & dosage	exanthema/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
axitinib/administration & dosage	fatigue/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
axitinib/administration & dosage	hepatitis autoimmune/etiology	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
axitinib/administration & dosage	hypophysitis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
axitinib/administration & dosage	ipilimumab/therapeutic use	0	1	0.0036027646835737	0.830190299122522	0.032258064516129	0.0067591691408641
axitinib/administration & dosage	myasthenia gravis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
axitinib/administration & dosage	myocarditis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
axitinib/administration & dosage	nephritis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
axitinib/administration & dosage	nivolumab/therapeutic use	0	1	0.00299295859196	0.830190299122522	0.021505376344086	0.0058034197088005
axitinib/administration & dosage	pruritus/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
axitinib/administration & dosage	pneumonia/chemically induced	1	1	0.0052037117615472	0.8192464059779487	0.0319148936170212	0.0091356041252636
bevacizumab/administration & dosage	carcinoma renal cell/drug therapy	0	1	0.0012219719371479	0.830190299122522	0.021505376344086	0.0026891839170452
bevacizumab/administration & dosage	diabetes mellitus type 1/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
bevacizumab/administration & dosage	exanthema/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
bevacizumab/administration & dosage	fatigue/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
bevacizumab/administration & dosage	hepatitis autoimmune/etiology	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
bevacizumab/administration & dosage	hypophysitis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
bevacizumab/administration & dosage	ipilimumab/therapeutic use	0	1	0.0036027646835737	0.830190299122522	0.032258064516129	0.0067591691408641
bevacizumab/administration & dosage	myasthenia gravis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
bevacizumab/administration & dosage	myocarditis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
bevacizumab/administration & dosage	nephritis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
bevacizumab/administration & dosage	nivolumab/therapeutic use	0	1	0.00299295859196	0.830190299122522	0.021505376344086	0.0058034197088005
bevacizumab/administration & dosage	pruritus/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
bevacizumab/administration & dosage	pneumonia/chemically induced	1	1	0.0052037117615472	0.8192464059779487	0.0319148936170212	0.0091356041252636
carcinoma renal cell/drug therapy	diabetes mellitus type 1/chemically induced	0	1	0.0012219719371479	0.830190299122522	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	exanthema/chemically induced	0	1	0.0012219719371479	0.830190299122522	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	fatigue/chemically induced	0	1	0.0012219719371479	0.830190299122522	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	hepatitis autoimmune/etiology	0	1	0.0012219719371479	0.830190299122522	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	hypophysitis/chemically induced	0	1	0.0012219719371479	0.830190299122522	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	inflammatory bowel diseases/drug therapy	0	1	0.0012219719371479	0.830190299122522	0.0638148667601683	0.0026891839170452
carcinoma renal cell/drug therapy	ipilimumab/therapeutic use	0	2	3.41405953174778e-07	0.584635003932401	0.0007012622720897	2.19327460827433e-06
carcinoma renal cell/drug therapy	myasthenia gravis/chemically induced	0	1	0.0012219719371479	0.830190299122522	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	myocarditis/chemically induced	0	1	0.0012219719371479	0.830190299122522	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	nephritis/chemically induced	0	1	0.0012219719371479	0.830190299122522	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	proton pump inhibitors/adverse effects	0	1	3.61856766772917e-10	0.830190299122522	0.021505376344086	3.7119500591544304e-09
carcinoma renal cell/drug therapy	pruritus/chemically induced	0	1	0.0012219719371479	0.830190299122522	0.021505376344086	0.0026891839170452
diabetes mellitus type 1/chemically induced	exanthema/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
diabetes mellitus type 1/chemically induced	fatigue/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
diabetes mellitus type 1/chemically induced	hepatitis autoimmune/etiology	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
diabetes mellitus type 1/chemically induced	hypophysitis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
diabetes mellitus type 1/chemically induced	ipilimumab/therapeutic use	0	1	0.0036027646835737	0.830190299122522	0.032258064516129	0.0067591691408641
diabetes mellitus type 1/chemically induced	myasthenia gravis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
diabetes mellitus type 1/chemically induced	myocarditis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
diabetes mellitus type 1/chemically induced	nephritis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
diabetes mellitus type 1/chemically induced	nivolumab/therapeutic use	0	1	0.00299295859196	0.830190299122522	0.021505376344086	0.0058034197088005
diabetes mellitus type 1/chemically induced	pruritus/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
diabetes mellitus type 1/chemically induced	pneumonia/chemically induced	1	1	0.0052037117615472	0.8192464059779487	0.0319148936170212	0.0091356041252636
exanthema/chemically induced	fatigue/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
exanthema/chemically induced	hepatitis autoimmune/etiology	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
exanthema/chemically induced	hypophysitis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
exanthema/chemically induced	ipilimumab/therapeutic use	0	1	0.0036027646835737	0.830190299122522	0.032258064516129	0.0067591691408641
exanthema/chemically induced	myasthenia gravis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
exanthema/chemically induced	myocarditis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
exanthema/chemically induced	nephritis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
exanthema/chemically induced	nivolumab/therapeutic use	0	1	0.00299295859196	0.830190299122522	0.021505376344086	0.0058034197088005
exanthema/chemically induced	pruritus/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
exanthema/chemically induced	pneumonia/chemically induced	1	1	0.0052037117615472	0.8192464059779487	0.0319148936170212	0.0091356041252636
fatigue/chemically induced	hepatitis autoimmune/etiology	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
fatigue/chemically induced	hypophysitis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
fatigue/chemically induced	ipilimumab/therapeutic use	0	1	0.0036027646835737	0.830190299122522	0.032258064516129	0.0067591691408641
fatigue/chemically induced	myasthenia gravis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
fatigue/chemically induced	myocarditis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
fatigue/chemically induced	nephritis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
fatigue/chemically induced	nivolumab/therapeutic use	0	1	0.00299295859196	0.830190299122522	0.021505376344086	0.0058034197088005
fatigue/chemically induced	pruritus/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
fatigue/chemically induced	pneumonia/chemically induced	1	1	0.0052037117615472	0.8192464059779487	0.0319148936170212	0.0091356041252636
hepatitis autoimmune/etiology	hypophysitis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
hepatitis autoimmune/etiology	ipilimumab/therapeutic use	0	1	0.0036027646835737	0.830190299122522	0.032258064516129	0.0067591691408641
hepatitis autoimmune/etiology	myasthenia gravis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
hepatitis autoimmune/etiology	myocarditis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
hepatitis autoimmune/etiology	nephritis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
hepatitis autoimmune/etiology	nivolumab/therapeutic use	0	1	0.00299295859196	0.830190299122522	0.021505376344086	0.0058034197088005
hepatitis autoimmune/etiology	pruritus/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
hepatitis autoimmune/etiology	pneumonia/chemically induced	1	1	0.0052037117615472	0.8192464059779487	0.0319148936170212	0.0091356041252636
hypophysitis/chemically induced	ipilimumab/therapeutic use	0	1	0.0036027646835737	0.830190299122522	0.032258064516129	0.0067591691408641
hypophysitis/chemically induced	myasthenia gravis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
hypophysitis/chemically induced	myocarditis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
hypophysitis/chemically induced	nephritis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
hypophysitis/chemically induced	nivolumab/therapeutic use	0	1	0.00299295859196	0.830190299122522	0.021505376344086	0.0058034197088005
hypophysitis/chemically induced	pruritus/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
hypophysitis/chemically induced	pneumonia/chemically induced	1	1	0.0052037117615472	0.8192464059779487	0.0319148936170212	0.0091356041252636
ipilimumab/therapeutic use	carcinoma non-small-cell lung/drug therapy	0	1	7.1540639148715e-05	0.830190299122522	0.0638148667601683	0.0002585218551055
ipilimumab/therapeutic use	inflammatory bowel diseases/drug therapy	0	1	0.0036027646835737	0.830190299122522	0.0946781129109319	0.0067591691408641
ipilimumab/therapeutic use	myasthenia gravis/chemically induced	0	1	0.0036027646835737	0.830190299122522	0.032258064516129	0.0067591691408641
ipilimumab/therapeutic use	myocarditis/chemically induced	0	1	0.0036027646835737	0.830190299122522	0.032258064516129	0.0067591691408641
ipilimumab/therapeutic use	nephritis/chemically induced	0	1	0.0036027646835737	0.830190299122522	0.032258064516129	0.0067591691408641
ipilimumab/therapeutic use	pneumonia/chemically induced	0	2	2.19354342352318e-05	0.584635003932401	0.0020883744586409	8.23874183480754e-05
ipilimumab/therapeutic use	proton pump inhibitors/adverse effects	0	1	1.4077731091966e-08	0.830190299122522	0.032258064516129	9.94826330498929e-08
ipilimumab/therapeutic use	pruritus/chemically induced	0	1	0.0036027646835737	0.830190299122522	0.032258064516129	0.0067591691408641
myasthenia gravis/chemically induced	myocarditis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
myasthenia gravis/chemically induced	nephritis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
myasthenia gravis/chemically induced	nivolumab/therapeutic use	0	1	0.00299295859196	0.830190299122522	0.021505376344086	0.0058034197088005
myasthenia gravis/chemically induced	pruritus/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
myasthenia gravis/chemically induced	pneumonia/chemically induced	1	1	0.0052037117615472	0.8192464059779487	0.0319148936170212	0.0091356041252636
myocarditis/chemically induced	nephritis/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
myocarditis/chemically induced	nivolumab/therapeutic use	0	1	0.00299295859196	0.830190299122522	0.021505376344086	0.0058034197088005
myocarditis/chemically induced	pruritus/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
myocarditis/chemically induced	pneumonia/chemically induced	1	1	0.0052037117615472	0.8192464059779487	0.0319148936170212	0.0091356041252636
nephritis/chemically induced	nivolumab/therapeutic use	0	1	0.00299295859196	0.830190299122522	0.021505376344086	0.0058034197088005
nephritis/chemically induced	pruritus/chemically induced	0	1	0.0002334339983105	0.830190299122522	0.010752688172043	0.0005814517869145
nephritis/chemically induced	pneumonia/chemically induced	1	1	0.0052037117615472	0.8192464059779487	0.0319148936170212	0.0091356041252636
nivolumab/therapeutic use	arthritis/chemically induced	0	1	1.91866149846787e-05	0.830190299122522	0.021505376344086	7.23479474125828e-05
nivolumab/therapeutic use	CHI3L1	0	1	1.91866149846787e-05	0.830190299122522	0.021505376344086	7.23479474125828e-05
nivolumab/therapeutic use	CXCL8	0	1	1.91866149846787e-05	0.830190299122522	0.021505376344086	7.23479474125828e-05
nivolumab/therapeutic use	glucocorticoids	0	1	1.91866149846787e-05	0.830190299122522	0.021505376344086	7.23479474125828e-05
nivolumab/therapeutic use	pruritus/chemically induced	0	1	0.00299295859196	0.830190299122522	0.021505376344086	0.0058034197088005
pruritus/chemically induced	pneumonia/chemically induced	1	1	0.0052037117615472	0.8192464059779487	0.0319148936170212	0.0091356041252636
AHR	IL22	0	1	1.4288104033255401e-10	0.830190299122522	0.021505376344086	1.4978957415083202e-09
AHR	tryptophan/pharmacology	0	1	0.0	0.830190299122522	0.010752688172043	0.0
IL22	BTLA	0	1	0.0006439898318757	0.830190299122522	0.021505376344086	0.0014984543892913
IL22	CD28	0	1	0.0006439898318757	0.830190299122522	0.021505376344086	0.0014984543892913
IL22	CSF2	0	1	0.0006439898318757	0.830190299122522	0.021505376344086	0.0014984543892913
IL22	gastrointestinal neoplasms/drug therapy	0	1	0.0006439898318757	0.830190299122522	0.021505376344086	0.0014984543892913
IL22	HAVCR2	0	1	0.0006439898318757	0.830190299122522	0.021505376344086	0.0014984543892913
IL22	IL15	0	1	0.0006439898318757	0.830190299122522	0.021505376344086	0.0014984543892913
IL22	IL17C	0	1	0.0006439898318757	0.830190299122522	0.021505376344086	0.0014984543892913
IL22	IL21	0	1	0.0006439898318757	0.830190299122522	0.021505376344086	0.0014984543892913
IL22	IL4	0	1	0.0006439898318757	0.830190299122522	0.021505376344086	0.0014984543892913
IL22	immune system diseases/drug therapy	0	1	0.0006439898318757	0.830190299122522	0.021505376344086	0.0014984543892913
IL22	LIF	0	1	0.0006439898318757	0.830190299122522	0.021505376344086	0.0014984543892913
IL22	tryptophan/pharmacology	0	1	1.4288104033255401e-10	0.830190299122522	0.021505376344086	1.4978957415083202e-09
IL22	IL6	1	1	0.0050362482931877	0.8192464059779487	0.0423244108899565	0.0089728790551117
anti-bacterial agents/adverse effects	clostridium infections/chemically induced	0	1	0.0	0.830190299122522	0.010752688172043	0.0
anti-bacterial agents/adverse effects	escherichia coli infections/drug therapy	0	1	0.0	0.830190299122522	0.010752688172043	0.0
anti-bacterial agents/adverse effects	virus diseases/etiology	0	1	0.0	0.830190299122522	0.010752688172043	0.0
clostridium infections/chemically induced	escherichia coli infections/drug therapy	0	1	0.0	0.830190299122522	0.010752688172043	0.0
clostridium infections/chemically induced	virus diseases/etiology	0	1	0.0	0.830190299122522	0.010752688172043	0.0
escherichia coli infections/drug therapy	virus diseases/etiology	0	1	0.0	0.830190299122522	0.010752688172043	0.0
anti-bacterial agents/pharmacology	antineoplastic agents immunological/adverse effects	0	1	0.0001577274046907	0.830190299122522	0.075268817204301	0.0004491699823134
anti-bacterial agents/pharmacology	colitis/etiology	0	1	6.54831243673826e-08	0.830190299122522	0.021505376344086	4.30833797561952e-07
anti-bacterial agents/pharmacology	dysbiosis/etiology	0	1	0.0	0.830190299122522	0.010752688172043	0.0
anti-bacterial agents/pharmacology	host microbial interactions/drug effects	0	1	0.0	0.830190299122522	0.010752688172043	0.0
anti-bacterial agents/pharmacology	metabolome/drug effects	0	1	0.0	0.830190299122522	0.010752688172043	0.0
anti-bacterial agents/pharmacology	neoplasms/complications	0	1	5.79199854744417e-09	0.830190299122522	0.032258064516129	4.18603531383465e-08
antineoplastic agents immunological/adverse effects	antibodies monoclonal/adverse effects	0	1	0.0029295317826157	0.830190299122522	0.075268817204301	0.0057564846974571
antineoplastic agents immunological/adverse effects	colitis ulcerative/chemically induced	0	1	0.0009302340538402	0.830190299122522	0.075268817204301	0.0021230700654632
antineoplastic agents immunological/adverse effects	ctla-4 antigen/antagonists & inhibitors	0	2	0.0011131493251242	0.584635003932401	0.0141870751968928	0.0025284391813537
antineoplastic agents immunological/adverse effects	cytomegalovirus infections/diagnosis	0	1	5.063311991904131e-09	0.830190299122522	0.075268817204301	3.71569203098195e-08
antineoplastic agents immunological/adverse effects	dysbiosis/etiology	0	1	0.0001577274046907	0.830190299122522	0.075268817204301	0.0004491699823134
antineoplastic agents immunological/adverse effects	hashimoto disease/chemically induced	0	1	0.0009302340538402	0.830190299122522	0.075268817204301	0.0021230700654632
antineoplastic agents immunological/adverse effects	host microbial interactions/drug effects	0	1	0.0001577274046907	0.830190299122522	0.075268817204301	0.0004491699823134
antineoplastic agents immunological/adverse effects	immune checkpoint inhibitors/adverse effects	0	7	0.0053254060985574	0.010308700389748	0.016270764526575	0.0097794752993721
antineoplastic agents immunological/adverse effects	lymphocytes/drug effects	0	1	0.0029295317826157	0.830190299122522	0.075268817204301	0.0057564846974571
antineoplastic agents immunological/adverse effects	metabolome/drug effects	0	1	0.0001577274046907	0.830190299122522	0.075268817204301	0.0004491699823134
antineoplastic agents immunological/adverse effects	neutrophils/drug effects	0	1	0.0029295317826157	0.830190299122522	0.075268817204301	0.0057564846974571
antineoplastic agents immunological/adverse effects	paclitaxel/therapeutic use	0	1	0.0009302340538402	0.830190299122522	0.075268817204301	0.0021230700654632
antineoplastic agents immunological/adverse effects	programmed cell death 1 receptor/antagonists & inhibitors	0	3	0.0049629267011769	0.347909608055624	0.012719967331643	0.0092203156239976
antineoplastic agents immunological/adverse effects	squamous cell carcinoma of head and neck/drug therapy	0	1	0.0009302340538402	0.830190299122522	0.075268817204301	0.0021230700654632
antineoplastic agents immunological/adverse effects	tongue neoplasms/drug therapy	0	1	0.0009302340538402	0.830190299122522	0.075268817204301	0.0021230700654632
antineoplastic agents immunological/adverse effects	vitamin d	0	1	4.50371576143915e-07	0.830190299122522	0.075268817204301	2.87394303438993e-06
antineoplastic agents immunological/adverse effects	vitamin d/administration & dosage	0	1	0.0029295317826157	0.830190299122522	0.075268817204301	0.0057564846974571
colitis/etiology	cd8-positive t-lymphocytes/immunology	0	1	0.000267839978386	0.830190299122522	0.021505376344086	0.0006602566909052
colitis/etiology	cytotoxicity immunologic	0	1	0.000267839978386	0.830190299122522	0.021505376344086	0.0006602566909052
colitis/etiology	drug-related side effects and adverse reactions/prevention & control	0	1	0.000267839978386	0.830190299122522	0.021505376344086	0.0006602566909052
colitis/etiology	dysbiosis/etiology	0	1	6.54831243673826e-08	0.830190299122522	0.021505376344086	4.30833797561952e-07
colitis/etiology	growth inhibitors/therapeutic use	0	1	0.000267839978386	0.830190299122522	0.021505376344086	0.0006602566909052
colitis/etiology	host microbial interactions/drug effects	0	1	6.54831243673826e-08	0.830190299122522	0.021505376344086	4.30833797561952e-07
colitis/etiology	lymphocytes tumor-infiltrating/immunology	0	1	0.000267839978386	0.830190299122522	0.021505376344086	0.0006602566909052
colitis/etiology	metabolome/drug effects	0	1	6.54831243673826e-08	0.830190299122522	0.021505376344086	4.30833797561952e-07
colitis/etiology	MTOR	0	1	0.000267839978386	0.830190299122522	0.021505376344086	0.0006602566909052
colitis/etiology	neoplasms/complications	0	1	0.0012943475198039	0.830190299122522	0.0638148667601683	0.0028224172203267
colitis/etiology	phosphatidylinositol 3-kinases/metabolism	0	1	0.000267839978386	0.830190299122522	0.021505376344086	0.0006602566909052
colitis/etiology	sirolimus/therapeutic use	0	1	0.000267839978386	0.830190299122522	0.021505376344086	0.0006602566909052
dysbiosis/etiology	host microbial interactions/drug effects	0	1	0.0	0.830190299122522	0.010752688172043	0.0
dysbiosis/etiology	metabolome/drug effects	0	1	0.0	0.830190299122522	0.010752688172043	0.0
dysbiosis/etiology	neoplasms/complications	0	1	5.79199854744417e-09	0.830190299122522	0.032258064516129	4.18603531383465e-08
host microbial interactions/drug effects	metabolome/drug effects	0	1	0.0	0.830190299122522	0.010752688172043	0.0
host microbial interactions/drug effects	neoplasms/complications	0	1	5.79199854744417e-09	0.830190299122522	0.032258064516129	4.18603531383465e-08
metabolome/drug effects	neoplasms/complications	0	1	5.79199854744417e-09	0.830190299122522	0.032258064516129	4.18603531383465e-08
neoplasms/complications	colitis/epidemiology	0	1	3.02429414844596e-10	0.830190299122522	0.032258064516129	3.1191098568837304e-09
neoplasms/complications	inflammatory bowel diseases/complications	0	1	3.03292073455808e-07	0.830190299122522	0.0638148667601683	1.95500431133e-06
antibodies monoclonal humanized	endometrial neoplasms/drug therapy	0	1	0.0	0.830190299122522	0.010752688172043	0.0
antibodies monoclonal humanized	neoplasm recurrence local/drug therapy	0	1	0.0	0.830190299122522	0.010752688172043	0.0
antibodies monoclonal humanized	immune checkpoint inhibitors	1	1	0.004953734053108	0.8192464059779487	0.3191489361702128	0.0088335817030947
endometrial neoplasms/drug therapy	neoplasm recurrence local/drug therapy	0	1	0.0	0.830190299122522	0.010752688172043	0.0
endometrial neoplasms/drug therapy	immune checkpoint inhibitors	1	1	0.004953734053108	0.8192464059779487	0.3191489361702128	0.0088335817030947
neoplasm recurrence local/drug therapy	immune checkpoint inhibitors	1	1	0.004953734053108	0.8192464059779487	0.3191489361702128	0.0088335817030947
antibodies monoclonal humanized/administration & dosage	dose-response relationship drug	0	1	2.16207951542202e-09	0.830190299122522	0.021505376344086	1.64352498622519e-08
antibodies monoclonal humanized/administration & dosage	drugs investigational/administration & dosage	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
antibodies monoclonal humanized/administration & dosage	immune checkpoint inhibitors/administration & dosage	0	1	0.0017670866860923	0.830190299122522	0.043010752688172	0.0037694605453253
antibodies monoclonal humanized/administration & dosage	neoplasms/diagnosis	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
antibodies monoclonal humanized/administration & dosage	pneumonia/chemically induced	0	1	9.10500023044714e-05	0.830190299122522	0.032258064516129	0.0002777578837603
dose-response relationship drug	drugs investigational/administration & dosage	0	1	2.16207951542202e-09	0.830190299122522	0.021505376344086	1.64352498622519e-08
dose-response relationship drug	feces	0	1	7.771561172376101e-16	0.830190299122522	0.021505376344086	1.66608300189816e-14
dose-response relationship drug	neoplasms/diagnosis	0	1	2.16207951542202e-09	0.830190299122522	0.021505376344086	1.64352498622519e-08
dose-response relationship drug	pneumonia/chemically induced	0	1	0.0019308727447	0.830190299122522	0.0638148667601683	0.0040050466235307
dose-response relationship drug	steroids/therapeutic use	0	1	2.0925394750293e-10	0.830190299122522	0.0427769985974754	2.18172968216169e-09
drugs investigational/administration & dosage	immune checkpoint inhibitors/administration & dosage	0	1	0.0017670866860923	0.830190299122522	0.043010752688172	0.0037694605453253
drugs investigational/administration & dosage	neoplasms/diagnosis	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
drugs investigational/administration & dosage	pneumonia/chemically induced	0	1	9.10500023044714e-05	0.830190299122522	0.032258064516129	0.0002777578837603
immune checkpoint inhibitors/administration & dosage	APC	0	2	0.0022669618381826	0.584635003932401	0.0014025245441795	0.0045434487261055
immune checkpoint inhibitors/administration & dosage	neoplasms/diagnosis	0	1	0.0017670866860923	0.830190299122522	0.043010752688172	0.0037694605453253
neoplasms/diagnosis	pneumonia/chemically induced	0	1	9.10500023044714e-05	0.830190299122522	0.032258064516129	0.0002777578837603
pneumonia/chemically induced	carcinoma non-small-cell lung/drug therapy	0	1	0.0002123977946096	0.830190299122522	0.0638148667601683	0.0005814517869145
antibodies monoclonal humanized/therapeutic use	infliximab/adverse effects	0	1	6.36879438076221e-12	0.830190299122522	0.043010752688172	9.068402745145001e-11
antibodies monoclonal humanized/therapeutic use	steroids/adverse effects	0	1	0.0	0.830190299122522	0.010752688172043	0.0
infliximab/adverse effects	colon/diagnostic imaging	0	1	1.69483587066921e-05	0.830190299122522	0.043010752688172	6.44172677537221e-05
infliximab/adverse effects	drug resistance/immunology	0	1	1.69483587066921e-05	0.830190299122522	0.043010752688172	6.44172677537221e-05
infliximab/adverse effects	glucocorticoids/pharmacology	0	1	1.69483587066921e-05	0.830190299122522	0.043010752688172	6.44172677537221e-05
infliximab/adverse effects	immunosuppressive agents/pharmacology	0	1	1.69483587066921e-05	0.830190299122522	0.043010752688172	6.44172677537221e-05
infliximab/adverse effects	intestinal mucosa/diagnostic imaging	0	1	1.69483587066921e-05	0.830190299122522	0.043010752688172	6.44172677537221e-05
infliximab/adverse effects	LTF	0	1	8.488771907622091e-10	0.830190299122522	0.043010752688172	7.74320237197327e-09
infliximab/adverse effects	melanoma/drug therapy	0	2	2.48187697959867e-06	0.584635003932401	0.0134138885892041	1.42204843155383e-05
infliximab/adverse effects	mucositis/chemically induced	0	1	1.69483587066921e-05	0.830190299122522	0.043010752688172	6.44172677537221e-05
infliximab/adverse effects	neoplasms	0	1	0.0003058560984983	0.830190299122522	0.163750819851802	0.0007520276236272
infliximab/adverse effects	steroids/adverse effects	0	1	6.36879438076221e-12	0.830190299122522	0.043010752688172	9.068402745145001e-11
antibodies monoclonal/adverse effects	ctla-4 antigen/antagonists & inhibitors	0	1	0.000426487876034	0.830190299122522	0.032258064516129	0.0010339756892922
antibodies monoclonal/adverse effects	lymphocytes/drug effects	0	1	9.98337412738692e-10	0.830190299122522	0.010752688172043	7.74320237197327e-09
antibodies monoclonal/adverse effects	neutrophils/drug effects	0	1	9.98337412738692e-10	0.830190299122522	0.010752688172043	7.74320237197327e-09
antibodies monoclonal/adverse effects	vitamin d/administration & dosage	0	1	9.98337412738692e-10	0.830190299122522	0.010752688172043	7.74320237197327e-09
ctla-4 antigen/antagonists & inhibitors	CTLA4	0	3	0.0025224336864024	0.347909608055624	0.0016953593391181	0.0050448673728049
ctla-4 antigen/antagonists & inhibitors	immunologic memory/drug effects	0	1	0.0012578068210133	0.830190299122522	0.032258064516129	0.0027490210933488
ctla-4 antigen/antagonists & inhibitors	interferon-gamma/metabolism	0	1	0.0012578068210133	0.830190299122522	0.032258064516129	0.0027490210933488
ctla-4 antigen/antagonists & inhibitors	lymphocytes/drug effects	0	1	0.000426487876034	0.830190299122522	0.032258064516129	0.0010339756892922
ctla-4 antigen/antagonists & inhibitors	neutrophils/drug effects	0	1	0.000426487876034	0.830190299122522	0.032258064516129	0.0010339756892922
ctla-4 antigen/antagonists & inhibitors	programmed cell death 1 receptor/antagonists & inhibitors	0	3	0.0004806528722617	0.347909608055624	0.0004315460135936	0.0011594003543304
ctla-4 antigen/antagonists & inhibitors	vitamin d/administration & dosage	0	1	0.000426487876034	0.830190299122522	0.032258064516129	0.0010339756892922
lymphocytes/drug effects	neutrophils/drug effects	0	1	9.98337412738692e-10	0.830190299122522	0.010752688172043	7.74320237197327e-09
lymphocytes/drug effects	vitamin d/administration & dosage	0	1	9.98337412738692e-10	0.830190299122522	0.010752688172043	7.74320237197327e-09
neutrophils/drug effects	vitamin d/administration & dosage	0	1	9.98337412738692e-10	0.830190299122522	0.010752688172043	7.74320237197327e-09
colitis ulcerative/chemically induced	hashimoto disease/chemically induced	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
colitis ulcerative/chemically induced	nivolumab/adverse effects	0	1	0.0036027646835737	0.830190299122522	0.129032258064516	0.0067591691408641
colitis ulcerative/chemically induced	paclitaxel/therapeutic use	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
colitis ulcerative/chemically induced	squamous cell carcinoma of head and neck/drug therapy	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
colitis ulcerative/chemically induced	tongue neoplasms/drug therapy	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
hashimoto disease/chemically induced	nivolumab/adverse effects	0	1	0.0036027646835737	0.830190299122522	0.129032258064516	0.0067591691408641
hashimoto disease/chemically induced	paclitaxel/therapeutic use	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
hashimoto disease/chemically induced	squamous cell carcinoma of head and neck/drug therapy	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
hashimoto disease/chemically induced	tongue neoplasms/drug therapy	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
immune checkpoint inhibitors/adverse effects	colitis/chemically induced	0	41	6.64030541791538e-05	1e-15	0.28552761772611	0.0002413276711882
immune checkpoint inhibitors/adverse effects	nivolumab/adverse effects	0	9	0.0016934163344379	0.0008903144156418	0.149573662209081	0.0036716345069405
immune checkpoint inhibitors/adverse effects	mycophenolic acid	1	1	0.0052037117615472	0.8192464059779487	0.5638297872340425	0.0091356041252636
immune checkpoint inhibitors/adverse effects	gastritis/chemically induced	1	1	0.0052037117615472	0.8192464059779487	0.5638297872340425	0.0091356041252636
immune checkpoint inhibitors/adverse effects	anti-bacterial agents	1	1	0.0052037117615472	0.8192464059779487	0.5638297872340425	0.0091356041252636
immune checkpoint inhibitors/adverse effects	adrenal cortex hormones/pharmacology	1	1	0.0052037117615472	0.8192464059779487	0.5638297872340425	0.0091356041252636
paclitaxel/therapeutic use	nivolumab/adverse effects	0	1	0.0036027646835737	0.830190299122522	0.129032258064516	0.0067591691408641
paclitaxel/therapeutic use	squamous cell carcinoma of head and neck/drug therapy	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
paclitaxel/therapeutic use	tongue neoplasms/drug therapy	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
programmed cell death 1 receptor/antagonists & inhibitors	colitis/epidemiology	0	1	0.0026251685810957	0.830190299122522	0.086021505376344	0.0052393531932329
squamous cell carcinoma of head and neck/drug therapy	nivolumab/adverse effects	0	1	0.0036027646835737	0.830190299122522	0.129032258064516	0.0067591691408641
squamous cell carcinoma of head and neck/drug therapy	tongue neoplasms/drug therapy	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
tongue neoplasms/drug therapy	nivolumab/adverse effects	0	1	0.0036027646835737	0.830190299122522	0.129032258064516	0.0067591691408641
vitamin d	melanoma/drug therapy	0	1	1.5989729540422102e-09	0.830190299122522	0.053763440860215	1.23515805518726e-08
APC	ARG1	0	1	0.0028052417422615	0.830190299122522	0.021505376344086	0.005535058163635
APC	azoxymethane/adverse effects	0	1	0.0028052417422615	0.830190299122522	0.021505376344086	0.005535058163635
APC	b7-h1 antigen/genetics	0	1	0.0052154676801927	0.830190299122522	0.021505376344086	0.0095868134237069
APC	colonic neoplasms/drug therapy	0	1	0.0028052417422615	0.830190299122522	0.021505376344086	0.005535058163635
APC	colorectal neoplasms/drug therapy	0	1	0.0052154676801927	0.830190299122522	0.021505376344086	0.0095868134237069
APC	dextran sulfate/adverse effects	0	1	0.0028052417422615	0.830190299122522	0.021505376344086	0.005535058163635
APC	gene expression regulation neoplastic	0	1	0.0052154676801927	0.830190299122522	0.021505376344086	0.0095868134237069
APC	ht29 cells	0	1	0.0052154676801927	0.830190299122522	0.021505376344086	0.0095868134237069
APC	interleukin-17/genetics	0	1	0.0052154676801927	0.830190299122522	0.021505376344086	0.0095868134237069
APC	lymphocytes tumor-infiltrating/metabolism	0	1	0.0052154676801927	0.830190299122522	0.021505376344086	0.0095868134237069
APC	micrornas/genetics	0	1	0.0052154676801927	0.830190299122522	0.021505376344086	0.0095868134237069
APC	MIR15B	0	1	0.0052154676801927	0.830190299122522	0.021505376344086	0.0095868134237069
APC	myeloid-derived suppressor cells/metabolism	0	1	0.0028052417422615	0.830190299122522	0.021505376344086	0.005535058163635
APC	NRF1	0	1	0.0052154676801927	0.830190299122522	0.021505376344086	0.0095868134237069
APC	PARP1	0	1	0.0028052417422615	0.830190299122522	0.021505376344086	0.005535058163635
APC	phthalazines/administration & dosage	0	1	0.0028052417422615	0.830190299122522	0.021505376344086	0.005535058163635
APC	piperazines/administration & dosage	0	1	0.0028052417422615	0.830190299122522	0.021505376344086	0.005535058163635
APC	poly(adp-ribose) polymerase inhibitors/administration & dosage	0	1	0.0028052417422615	0.830190299122522	0.021505376344086	0.005535058163635
APC	t-lymphocytes cytotoxic/immunology	0	1	0.0052154676801927	0.830190299122522	0.021505376344086	0.0095868134237069
APC	TIPARP	0	1	0.0028052417422615	0.830190299122522	0.021505376344086	0.005535058163635
APC	tumor microenvironment/drug effects	0	1	0.0052154676801927	0.830190299122522	0.021505376344086	0.0095868134237069
ARG1	azoxymethane/adverse effects	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
ARG1	cell line tumor	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
ARG1	colonic neoplasms/drug therapy	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
ARG1	dextran sulfate/adverse effects	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
ARG1	drug synergism	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
ARG1	myeloid-derived suppressor cells/metabolism	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
ARG1	PARP1	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
ARG1	phthalazines/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
ARG1	piperazines/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
ARG1	poly(adp-ribose) polymerase inhibitors/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
ARG1	TIPARP	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
azoxymethane/adverse effects	cell line tumor	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
azoxymethane/adverse effects	colonic neoplasms/drug therapy	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
azoxymethane/adverse effects	dextran sulfate/adverse effects	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
azoxymethane/adverse effects	drug synergism	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
azoxymethane/adverse effects	myeloid-derived suppressor cells/metabolism	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
azoxymethane/adverse effects	PARP1	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
azoxymethane/adverse effects	phthalazines/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
azoxymethane/adverse effects	piperazines/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
azoxymethane/adverse effects	poly(adp-ribose) polymerase inhibitors/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
azoxymethane/adverse effects	TIPARP	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
b7-h1 antigen/genetics	colorectal neoplasms/drug therapy	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
b7-h1 antigen/genetics	gene expression regulation neoplastic	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
b7-h1 antigen/genetics	ht29 cells	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
b7-h1 antigen/genetics	IL17A	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
b7-h1 antigen/genetics	interleukin-17/genetics	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
b7-h1 antigen/genetics	lymphocytes tumor-infiltrating/metabolism	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
b7-h1 antigen/genetics	micrornas/genetics	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
b7-h1 antigen/genetics	MIR15B	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
b7-h1 antigen/genetics	NRF1	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
b7-h1 antigen/genetics	t-lymphocytes cytotoxic/immunology	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
b7-h1 antigen/genetics	tumor microenvironment/drug effects	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
colonic neoplasms/drug therapy	cell line tumor	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
colonic neoplasms/drug therapy	dextran sulfate/adverse effects	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
colonic neoplasms/drug therapy	drug synergism	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
colonic neoplasms/drug therapy	myeloid-derived suppressor cells/metabolism	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
colonic neoplasms/drug therapy	PARP1	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
colonic neoplasms/drug therapy	phthalazines/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
colonic neoplasms/drug therapy	piperazines/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
colonic neoplasms/drug therapy	poly(adp-ribose) polymerase inhibitors/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
colonic neoplasms/drug therapy	TIPARP	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
colorectal neoplasms/drug therapy	gene expression regulation neoplastic	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
colorectal neoplasms/drug therapy	ht29 cells	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
colorectal neoplasms/drug therapy	IL17A	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
colorectal neoplasms/drug therapy	interleukin-17/genetics	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
colorectal neoplasms/drug therapy	lymphocytes tumor-infiltrating/metabolism	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
colorectal neoplasms/drug therapy	micrornas/genetics	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
colorectal neoplasms/drug therapy	MIR15B	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
colorectal neoplasms/drug therapy	NRF1	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
colorectal neoplasms/drug therapy	t-lymphocytes cytotoxic/immunology	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
colorectal neoplasms/drug therapy	tumor microenvironment/drug effects	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
dextran sulfate/adverse effects	cell line tumor	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
dextran sulfate/adverse effects	drug synergism	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
dextran sulfate/adverse effects	myeloid-derived suppressor cells/metabolism	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
dextran sulfate/adverse effects	PARP1	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
dextran sulfate/adverse effects	phthalazines/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
dextran sulfate/adverse effects	piperazines/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
dextran sulfate/adverse effects	poly(adp-ribose) polymerase inhibitors/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
dextran sulfate/adverse effects	TIPARP	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
gene expression regulation neoplastic	ht29 cells	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
gene expression regulation neoplastic	IL17A	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
gene expression regulation neoplastic	interleukin-17/genetics	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
gene expression regulation neoplastic	lymphocytes tumor-infiltrating/metabolism	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
gene expression regulation neoplastic	micrornas/genetics	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
gene expression regulation neoplastic	MIR15B	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
gene expression regulation neoplastic	NRF1	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
gene expression regulation neoplastic	t-lymphocytes cytotoxic/immunology	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
gene expression regulation neoplastic	tumor microenvironment/drug effects	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
ht29 cells	IL17A	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
ht29 cells	interleukin-17/genetics	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
ht29 cells	lymphocytes tumor-infiltrating/metabolism	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
ht29 cells	micrornas/genetics	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
ht29 cells	MIR15B	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
ht29 cells	NRF1	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
ht29 cells	t-lymphocytes cytotoxic/immunology	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
ht29 cells	tumor microenvironment/drug effects	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
interleukin-17/genetics	IL17A	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
interleukin-17/genetics	lymphocytes tumor-infiltrating/metabolism	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
interleukin-17/genetics	micrornas/genetics	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
interleukin-17/genetics	MIR15B	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
interleukin-17/genetics	NRF1	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
interleukin-17/genetics	t-lymphocytes cytotoxic/immunology	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
interleukin-17/genetics	tumor microenvironment/drug effects	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
lymphocytes tumor-infiltrating/metabolism	IL17A	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
lymphocytes tumor-infiltrating/metabolism	micrornas/genetics	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
lymphocytes tumor-infiltrating/metabolism	MIR15B	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
lymphocytes tumor-infiltrating/metabolism	NRF1	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
lymphocytes tumor-infiltrating/metabolism	t-lymphocytes cytotoxic/immunology	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
lymphocytes tumor-infiltrating/metabolism	tumor microenvironment/drug effects	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
micrornas/genetics	IL17A	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
micrornas/genetics	MIR15B	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
micrornas/genetics	NRF1	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
micrornas/genetics	t-lymphocytes cytotoxic/immunology	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
micrornas/genetics	tumor microenvironment/drug effects	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
MIR15B	IL17A	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
MIR15B	NRF1	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
MIR15B	t-lymphocytes cytotoxic/immunology	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
MIR15B	tumor microenvironment/drug effects	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
myeloid-derived suppressor cells/metabolism	cell line tumor	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
myeloid-derived suppressor cells/metabolism	drug synergism	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
myeloid-derived suppressor cells/metabolism	PARP1	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
myeloid-derived suppressor cells/metabolism	phthalazines/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
myeloid-derived suppressor cells/metabolism	piperazines/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
myeloid-derived suppressor cells/metabolism	poly(adp-ribose) polymerase inhibitors/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
myeloid-derived suppressor cells/metabolism	TIPARP	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
NRF1	IL17A	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
NRF1	t-lymphocytes cytotoxic/immunology	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
NRF1	tumor microenvironment/drug effects	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
PARP1	cell line tumor	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
PARP1	drug synergism	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
PARP1	phthalazines/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
PARP1	piperazines/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
PARP1	poly(adp-ribose) polymerase inhibitors/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
PARP1	TIPARP	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
phthalazines/administration & dosage	cell line tumor	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
phthalazines/administration & dosage	drug synergism	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
phthalazines/administration & dosage	piperazines/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
phthalazines/administration & dosage	poly(adp-ribose) polymerase inhibitors/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
phthalazines/administration & dosage	TIPARP	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
piperazines/administration & dosage	cell line tumor	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
piperazines/administration & dosage	drug synergism	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
piperazines/administration & dosage	poly(adp-ribose) polymerase inhibitors/administration & dosage	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
piperazines/administration & dosage	TIPARP	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
poly(adp-ribose) polymerase inhibitors/administration & dosage	cell line tumor	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
poly(adp-ribose) polymerase inhibitors/administration & dosage	drug synergism	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
poly(adp-ribose) polymerase inhibitors/administration & dosage	TIPARP	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
t-lymphocytes cytotoxic/immunology	IL17A	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
t-lymphocytes cytotoxic/immunology	tumor microenvironment/drug effects	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
TIPARP	cell line tumor	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
TIPARP	drug synergism	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
tumor microenvironment/drug effects	IL17A	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
cell line tumor	cd8-positive t-lymphocytes/immunology	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
cell line tumor	cytotoxicity immunologic	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
cell line tumor	drug synergism	0	2	2.30042179798495e-05	0.584635003932401	0.0002337540906965	8.62319212289841e-05
cell line tumor	drug-related side effects and adverse reactions/prevention & control	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
cell line tumor	growth inhibitors/therapeutic use	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
cell line tumor	lymphocytes tumor-infiltrating/immunology	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
cell line tumor	MTOR	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
cell line tumor	phosphatidylinositol 3-kinases/metabolism	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
cell line tumor	sirolimus/therapeutic use	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
drug synergism	cd8-positive t-lymphocytes/immunology	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
drug synergism	cytotoxicity immunologic	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
drug synergism	drug-related side effects and adverse reactions/prevention & control	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
drug synergism	growth inhibitors/therapeutic use	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
drug synergism	lymphocytes tumor-infiltrating/immunology	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
drug synergism	MTOR	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
drug synergism	phosphatidylinositol 3-kinases/metabolism	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
drug synergism	sirolimus/therapeutic use	0	1	0.0019794334203299	0.830190299122522	0.021505376344086	0.0040050466235307
arthritis/chemically induced	CHI3L1	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
arthritis/chemically induced	CXCL8	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
arthritis/chemically induced	glucocorticoids	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
arthritis/chemically induced	IL17A	0	1	1.3102028466272e-05	0.830190299122522	0.021505376344086	5.06045957766131e-05
arthritis/chemically induced	IL6	0	1	1.3102028466272e-05	0.830190299122522	0.021505376344086	5.06045957766131e-05
CHI3L1	CXCL8	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
CHI3L1	glucocorticoids	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
CHI3L1	IL17A	0	1	1.3102028466272e-05	0.830190299122522	0.021505376344086	5.06045957766131e-05
CHI3L1	IL6	0	1	1.3102028466272e-05	0.830190299122522	0.021505376344086	5.06045957766131e-05
CXCL8	glucocorticoids	0	1	6.98330282489224e-14	0.830190299122522	0.010752688172043	1.11967578066339e-12
CXCL8	IL17A	0	1	1.3102028466272e-05	0.830190299122522	0.021505376344086	5.06045957766131e-05
CXCL8	IL6	0	1	1.3102028466272e-05	0.830190299122522	0.021505376344086	5.06045957766131e-05
glucocorticoids	IL17A	0	1	1.3102028466272e-05	0.830190299122522	0.021505376344086	5.06045957766131e-05
glucocorticoids	IL6	0	1	1.3102028466272e-05	0.830190299122522	0.021505376344086	5.06045957766131e-05
IL6	BTLA	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
IL6	CD28	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
IL6	CSF2	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
IL6	gastrointestinal neoplasms/drug therapy	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
IL6	HAVCR2	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
IL6	IL15	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
IL6	IL17C	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
IL6	IL21	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
IL6	IL4	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
IL6	immune system diseases/drug therapy	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
IL6	LIF	0	1	0.0017899010765538	0.830190299122522	0.021505376344086	0.0037694605453253
CD274	CTLA4	0	7	0.0020080863838891	0.010308700389748	0.0003490778454898	0.0040587169708268
CD274	PDCD1	0	13	0.0005382898811121	2.38197855033722e-06	1.55572732193422e-07	0.0012774341954751
b7-h1 antigen/metabolism	colitis/diagnosis	0	1	1.56541446472147e-14	0.830190299122522	0.021505376344086	3.1774582964772e-13
b7-h1 antigen/metabolism	gastrointestinal tract/metabolism	0	1	0.0	0.830190299122522	0.010752688172043	0.0
b7-h1 antigen/metabolism	inflammatory bowel diseases	0	1	1.95732319241415e-13	0.830190299122522	0.021505376344086	3.0117521380050002e-12
b7-h1 antigen/metabolism	programmed cell death 1 receptor/metabolism	0	1	0.0	0.830190299122522	0.010752688172043	0.0
colitis/diagnosis	disease susceptibility	0	1	0.0	0.830190299122522	0.021505376344086	0.0
colitis/diagnosis	gastrointestinal tract/metabolism	0	1	1.56541446472147e-14	0.830190299122522	0.021505376344086	3.1774582964772e-13
colitis/diagnosis	inflammatory bowel diseases	0	1	5.063311991904131e-09	0.830190299122522	0.0427769985974754	3.71569203098195e-08
colitis/diagnosis	postoperative complications	0	1	0.0	0.830190299122522	0.021505376344086	0.0
colitis/diagnosis	programmed cell death 1 receptor/metabolism	0	1	1.56541446472147e-14	0.830190299122522	0.021505376344086	3.1774582964772e-13
gastrointestinal tract/metabolism	inflammatory bowel diseases	0	1	1.95732319241415e-13	0.830190299122522	0.021505376344086	3.0117521380050002e-12
gastrointestinal tract/metabolism	programmed cell death 1 receptor/metabolism	0	1	0.0	0.830190299122522	0.010752688172043	0.0
inflammatory bowel diseases	colitis	0	1	5.56643996285633e-06	0.830190299122522	0.0846189808321645	3.17037834302384e-05
inflammatory bowel diseases	diarrhea	0	1	1.95732319241415e-13	0.830190299122522	0.0427769985974754	3.0117521380050002e-12
inflammatory bowel diseases	neoplasms	0	1	2.36599509539914e-07	0.830190299122522	0.0846189808321645	1.53548253129985e-06
inflammatory bowel diseases	programmed cell death 1 receptor/metabolism	0	1	1.95732319241415e-13	0.830190299122522	0.021505376344086	3.0117521380050002e-12
inflammatory bowel diseases	recurrence	0	1	0.0	0.830190299122522	0.021505376344086	0.0
biomarkers/analysis	colitis/drug therapy	0	1	2.25073886195304e-08	0.830190299122522	0.032258064516129	1.50681043810751e-07
biomarkers/analysis	feces/chemistry	0	1	0.0	0.830190299122522	0.010752688172043	0.0
biomarkers/analysis	leukocyte l1 antigen complex/analysis	0	1	0.0	0.830190299122522	0.010752688172043	0.0
biomarkers/analysis	recurrence	1	1	0.0016585720850001	0.8192464059779487	0.0423244108899565	0.0032722311928437
biomarkers/analysis	antineoplastic agents/adverse effects	1	1	0.0002818746185764	0.8192464059779487	0.0212765957446808	0.0006571705393096
biomarkers/analysis	intestinal mucosa/chemistry	1	1	0.0002818746185764	0.8192464059779487	0.0212765957446808	0.0006571705393096
biomarkers/analysis	leukemia lymphocytic chronic b-cell/drug therapy	1	1	0.0002818746185764	0.8192464059779487	0.0212765957446808	0.0006571705393096
biomarkers/analysis	class i phosphatidylinositol 3-kinases/antagonists & inhibitors	1	1	0.0002818746185764	0.8192464059779487	0.0212765957446808	0.0006571705393096
biomarkers/analysis	purines/adverse effects	1	1	0.0002818746185764	0.8192464059779487	0.0212765957446808	0.0006571705393096
biomarkers/analysis	colon/chemistry	1	1	0.0002818746185764	0.8192464059779487	0.0212765957446808	0.0006571705393096
biomarkers/analysis	lymphocytosis/chemically induced	1	1	0.0002818746185764	0.8192464059779487	0.0212765957446808	0.0006571705393096
biomarkers/analysis	protein kinase inhibitors/adverse effects	1	1	0.0002818746185764	0.8192464059779487	0.0212765957446808	0.0006571705393096
biomarkers/analysis	apoptosis/drug effects	1	1	0.0002818746185764	0.8192464059779487	0.0212765957446808	0.0006571705393096
biomarkers/analysis	quinazolinones/adverse effects	1	1	0.0002818746185764	0.8192464059779487	0.0212765957446808	0.0006571705393096
biomarkers/analysis	lymphoma non-hodgkin/drug therapy	1	1	0.0002818746185764	0.8192464059779487	0.0212765957446808	0.0006571705393096
biomarkers/analysis	PIK3CD	1	1	0.0002818746185764	0.8192464059779487	0.0212765957446808	0.0006571705393096
colitis/drug therapy	cd8-positive t-lymphocytes/cytology	0	1	0.0004982368131516	0.830190299122522	0.032258064516129	0.0011838553418347
colitis/drug therapy	chemokines/metabolism	0	1	0.0004982368131516	0.830190299122522	0.032258064516129	0.0011838553418347
colitis/drug therapy	ctla-4 antigen/immunology	0	1	0.0004982368131516	0.830190299122522	0.032258064516129	0.0011838553418347
colitis/drug therapy	diarrhea/therapy	0	1	1.88737914186277e-15	0.830190299122522	0.032258064516129	3.9572740688727e-14
colitis/drug therapy	feces/chemistry	0	1	2.25073886195304e-08	0.830190299122522	0.032258064516129	1.50681043810751e-07
colitis/drug therapy	gene expression regulation/genetics	0	1	0.0004982368131516	0.830190299122522	0.032258064516129	0.0011838553418347
colitis/drug therapy	leukocyte l1 antigen complex/analysis	0	1	2.25073886195304e-08	0.830190299122522	0.032258064516129	1.50681043810751e-07
colitis/drug therapy	melanoma/genetics	0	1	0.0004982368131516	0.830190299122522	0.032258064516129	0.0011838553418347
colitis/drug therapy	multigene family	0	1	0.0004982368131516	0.830190299122522	0.032258064516129	0.0011838553418347
colitis/drug therapy	myeloid cells/cytology	0	1	0.0004982368131516	0.830190299122522	0.032258064516129	0.0011838553418347
colitis/drug therapy	neoplasms/therapy	0	1	1.88737914186277e-15	0.830190299122522	0.032258064516129	3.9572740688727e-14
colitis/drug therapy	receptors antigen t-cell/genetics	0	1	0.0004982368131516	0.830190299122522	0.032258064516129	0.0011838553418347
colitis/drug therapy	receptors cxcr3/genetics	0	1	0.0004982368131516	0.830190299122522	0.032258064516129	0.0011838553418347
colitis/drug therapy	receptors cxcr6/genetics	0	1	0.0004982368131516	0.830190299122522	0.032258064516129	0.0011838553418347
colitis/drug therapy	t-lymphocytes regulatory/cytology	0	1	0.0004982368131516	0.830190299122522	0.032258064516129	0.0011838553418347
feces/chemistry	leukocyte l1 antigen complex/analysis	0	1	0.0	0.830190299122522	0.010752688172043	0.0
BTLA	CD28	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
BTLA	CSF2	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
BTLA	gastrointestinal neoplasms/drug therapy	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
BTLA	HAVCR2	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
BTLA	IL15	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
BTLA	IL17C	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
BTLA	IL21	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
BTLA	IL4	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
BTLA	immune system diseases/drug therapy	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
BTLA	LIF	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
CD28	CSF2	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
CD28	gastrointestinal neoplasms/drug therapy	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
CD28	HAVCR2	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
CD28	IL15	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
CD28	IL17C	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
CD28	IL21	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
CD28	IL4	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
CD28	immune system diseases/drug therapy	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
CD28	LIF	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
CSF2	gastrointestinal neoplasms/drug therapy	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
CSF2	HAVCR2	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
CSF2	IL15	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
CSF2	IL17C	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
CSF2	IL21	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
CSF2	IL4	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
CSF2	immune system diseases/drug therapy	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
CSF2	LIF	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
gastrointestinal neoplasms/drug therapy	HAVCR2	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
gastrointestinal neoplasms/drug therapy	IL15	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
gastrointestinal neoplasms/drug therapy	IL17C	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
gastrointestinal neoplasms/drug therapy	IL21	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
gastrointestinal neoplasms/drug therapy	IL4	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
gastrointestinal neoplasms/drug therapy	immune system diseases/drug therapy	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
gastrointestinal neoplasms/drug therapy	LIF	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
HAVCR2	IL15	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
HAVCR2	IL17C	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
HAVCR2	IL21	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
HAVCR2	IL4	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
HAVCR2	immune system diseases/drug therapy	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
HAVCR2	LIF	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
IL15	IL17C	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
IL15	IL21	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
IL15	IL4	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
IL15	immune system diseases/drug therapy	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
IL15	LIF	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
IL17C	IL21	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
IL17C	IL4	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
IL17C	immune system diseases/drug therapy	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
IL17C	LIF	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
IL21	IL4	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
IL21	immune system diseases/drug therapy	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
IL21	LIF	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
IL4	immune system diseases/drug therapy	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
IL4	LIF	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
immune system diseases/drug therapy	LIF	0	1	9.37505645396408e-05	0.830190299122522	0.010752688172043	0.0002777578837603
carcinoma non-small-cell lung	cd8-positive t-lymphocytes	0	1	0.0	0.830190299122522	0.010752688172043	0.0
carcinoma non-small-cell lung	immune checkpoint inhibitors	0	1	0.0003476938855124	0.830190299122522	0.32258064516129	0.0008472540658465
cd8-positive t-lymphocytes	immune checkpoint inhibitors	0	1	0.0003476938855124	0.830190299122522	0.32258064516129	0.0008472540658465
immune checkpoint inhibitors	colitis	0	3	6.68308462309364e-05	0.347909608055624	0.0969899665551839	0.000242420636138
immune checkpoint inhibitors	colitis microscopic/chemically induced	0	2	8.11341549500355e-10	0.584635003932401	0.101683029453015	7.74320237197327e-09
immune checkpoint inhibitors	colitis ulcerative	0	1	3.02429414844596e-10	0.830190299122522	0.32258064516129	3.1191098568837304e-09
immune checkpoint inhibitors	colitis/chemically induced	0	21	3.34409855997642e-05	8.37008936595782e-13	0.814358314952549	0.0001229391146904
immune checkpoint inhibitors	colitis/therapy	0	1	9.99540715695968e-06	0.830190299122522	0.32258064516129	4.04909487377475e-05
immune checkpoint inhibitors	crohn disease/drug therapy	0	1	9.99540715695968e-06	0.830190299122522	0.32258064516129	4.04909487377475e-05
immune checkpoint inhibitors	cytomegalovirus infections/complications	0	1	9.99540715695968e-06	0.830190299122522	0.32258064516129	4.04909487377475e-05
immune checkpoint inhibitors	diarrhea	0	2	5.90933778177316e-06	0.584635003932401	0.101683029453015	3.35565966893547e-05
immune checkpoint inhibitors	diarrhea/therapy	0	1	0.0003476938855124	0.830190299122522	0.32258064516129	0.0008472540658465
immune checkpoint inhibitors	esophagitis	0	1	0.0003476938855124	0.830190299122522	0.32258064516129	0.0008472540658465
immune checkpoint inhibitors	immunologic factors	0	2	8.11341549500355e-10	0.584635003932401	0.101683029453015	7.74320237197327e-09
immune checkpoint inhibitors	lung neoplasms	0	1	0.0003476938855124	0.830190299122522	0.32258064516129	0.0008472540658465
immune checkpoint inhibitors	neoplasms	0	2	0.0025310276064748	0.584635003932401	0.387959866220736	0.0050567546315748
immune checkpoint inhibitors	neoplasms/therapy	0	1	0.0003476938855124	0.830190299122522	0.32258064516129	0.0008472540658465
immune checkpoint inhibitors	prednisolone/therapeutic use	0	1	0.0021298880586121	0.830190299122522	0.32258064516129	0.0043003454135787
immune checkpoint inhibitors	ulcer/chemically induced	0	1	0.0003476938855124	0.830190299122522	0.32258064516129	0.0008472540658465
immune checkpoint inhibitors	LTF	1	1	0.004953734053108	0.8192464059779487	0.3191489361702128	0.0088335817030947
carcinoma non-small-cell lung/drug therapy	nivolumab/adverse effects	1	1	0.0045533020759077	0.8192464059779487	0.240219629375429	0.0081551678971482
inflammatory bowel diseases/drug therapy	CD4	0	1	0.0002334339983105	0.830190299122522	0.0638148667601683	0.0005814517869145
inflammatory bowel diseases/drug therapy	CD68	0	1	0.0002334339983105	0.830190299122522	0.0638148667601683	0.0005814517869145
inflammatory bowel diseases/drug therapy	colitis	0	1	0.0002334339983105	0.830190299122522	0.124855509147234	0.0005814517869145
inflammatory bowel diseases/drug therapy	CTLA4	0	2	0.0045640144008352	0.584635003932401	0.042892591279688	0.0085206844195631
inflammatory bowel diseases/drug therapy	proton pump inhibitors/adverse effects	0	1	1.2526646386845599e-12	0.830190299122522	0.032258064516129	1.8672532270391797e-11
CTLA4	colitis	0	2	0.0045640144008352	0.584635003932401	0.0795123530046391	0.0085206844195631
CTLA4	PDCD1	0	11	0.001293939617514	5.36975220686589e-05	7.40082614672845e-07	0.0028224172203267
PDCD1	inflammatory bowel diseases/complications	1	2	0.0053956230889646	0.5658111483402343	0.0686341798215511	0.0094643775593189
CD4	CD68	0	2	1.88182802673964e-13	0.584635003932401	0.0002337540906965	2.9921065625160297e-12
CD4	cd8-positive t-lymphocytes/drug effects	0	1	0.0012219719371479	0.830190299122522	0.0427769985974754	0.0026891839170452
CD4	CD8A	0	2	0.0002095106790775	0.584635003932401	0.0023375409069658	0.0005814517869145
CD4	colitis ulcerative/immunology	0	1	0.0012219719371479	0.830190299122522	0.0427769985974754	0.0026891839170452
CD4	crohn disease/immunology	0	1	6.08395890666635e-07	0.830190299122522	0.021505376344086	3.69687694073866e-06
CD4	graft vs host disease/immunology	0	1	6.08395890666635e-07	0.830190299122522	0.021505376344086	3.69687694073866e-06
CD4	macrophages/drug effects	0	1	6.08395890666635e-07	0.830190299122522	0.021505376344086	3.69687694073866e-06
CD4	phenotype	0	1	0.0012219719371479	0.830190299122522	0.0427769985974754	0.0026891839170452
CD68	cd8-positive t-lymphocytes/drug effects	0	1	0.0012219719371479	0.830190299122522	0.0427769985974754	0.0026891839170452
CD68	CD8A	0	2	0.0002095106790775	0.584635003932401	0.0023375409069658	0.0005814517869145
CD68	colitis ulcerative/immunology	0	1	0.0012219719371479	0.830190299122522	0.0427769985974754	0.0026891839170452
CD68	crohn disease/immunology	0	1	6.08395890666635e-07	0.830190299122522	0.021505376344086	3.69687694073866e-06
CD68	graft vs host disease/immunology	0	1	6.08395890666635e-07	0.830190299122522	0.021505376344086	3.69687694073866e-06
CD68	macrophages/drug effects	0	1	6.08395890666635e-07	0.830190299122522	0.021505376344086	3.69687694073866e-06
CD68	phenotype	0	1	0.0012219719371479	0.830190299122522	0.0427769985974754	0.0026891839170452
cd8-positive t-lymphocytes/drug effects	CD8A	0	2	0.0013552885133465	0.584635003932401	0.0023375409069658	0.0029452055620332
cd8-positive t-lymphocytes/drug effects	colitis ulcerative/immunology	0	2	1.40216387389813e-08	0.584635003932401	0.0002337540906965	9.94826330498929e-08
cd8-positive t-lymphocytes/drug effects	crohn disease/immunology	0	1	1.09558519411079e-05	0.830190299122522	0.021505376344086	4.30118631762015e-05
cd8-positive t-lymphocytes/drug effects	graft vs host disease/immunology	0	1	1.09558519411079e-05	0.830190299122522	0.021505376344086	4.30118631762015e-05
cd8-positive t-lymphocytes/drug effects	immunologic memory/drug effects	0	1	0.000124270133592	0.830190299122522	0.021505376344086	0.0003619960532727
cd8-positive t-lymphocytes/drug effects	interferon-gamma/metabolism	0	1	0.000124270133592	0.830190299122522	0.021505376344086	0.0003619960532727
cd8-positive t-lymphocytes/drug effects	macrophages/drug effects	0	1	1.09558519411079e-05	0.830190299122522	0.021505376344086	4.30118631762015e-05
cd8-positive t-lymphocytes/drug effects	phenotype	0	2	1.40216387389813e-08	0.584635003932401	0.0002337540906965	9.94826330498929e-08
cd8-positive t-lymphocytes/drug effects	piperidines/therapeutic use	0	1	0.0022342109308476	0.830190299122522	0.0427769985974754	0.0044825178297132
cd8-positive t-lymphocytes/drug effects	pyrimidines/therapeutic use	0	1	0.0022342109308476	0.830190299122522	0.0427769985974754	0.0044825178297132
CD8A	colitis ulcerative/immunology	0	2	0.0013552885133465	0.584635003932401	0.0023375409069658	0.0029452055620332
CD8A	phenotype	0	2	0.0013552885133465	0.584635003932401	0.0023375409069658	0.0029452055620332
colitis ulcerative/immunology	crohn disease/immunology	0	1	1.09558519411079e-05	0.830190299122522	0.021505376344086	4.30118631762015e-05
colitis ulcerative/immunology	graft vs host disease/immunology	0	1	1.09558519411079e-05	0.830190299122522	0.021505376344086	4.30118631762015e-05
colitis ulcerative/immunology	immunologic memory/drug effects	0	1	0.000124270133592	0.830190299122522	0.021505376344086	0.0003619960532727
colitis ulcerative/immunology	interferon-gamma/metabolism	0	1	0.000124270133592	0.830190299122522	0.021505376344086	0.0003619960532727
colitis ulcerative/immunology	macrophages/drug effects	0	1	1.09558519411079e-05	0.830190299122522	0.021505376344086	4.30118631762015e-05
colitis ulcerative/immunology	phenotype	0	2	1.40216387389813e-08	0.584635003932401	0.0002337540906965	9.94826330498929e-08
colitis ulcerative/immunology	piperidines/therapeutic use	0	1	0.0022342109308476	0.830190299122522	0.0427769985974754	0.0044825178297132
colitis ulcerative/immunology	pyrimidines/therapeutic use	0	1	0.0022342109308476	0.830190299122522	0.0427769985974754	0.0044825178297132
crohn disease/immunology	graft vs host disease/immunology	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
crohn disease/immunology	macrophages/drug effects	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
crohn disease/immunology	phenotype	0	1	1.09558519411079e-05	0.830190299122522	0.021505376344086	4.30118631762015e-05
graft vs host disease/immunology	macrophages/drug effects	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
graft vs host disease/immunology	phenotype	0	1	1.09558519411079e-05	0.830190299122522	0.021505376344086	4.30118631762015e-05
macrophages/drug effects	phenotype	0	1	1.09558519411079e-05	0.830190299122522	0.021505376344086	4.30118631762015e-05
phenotype	immunologic memory/drug effects	0	1	0.000124270133592	0.830190299122522	0.021505376344086	0.0003619960532727
phenotype	interferon-gamma/metabolism	0	1	0.000124270133592	0.830190299122522	0.021505376344086	0.0003619960532727
phenotype	piperidines/therapeutic use	0	1	0.0022342109308476	0.830190299122522	0.0427769985974754	0.0044825178297132
phenotype	pyrimidines/therapeutic use	0	1	0.0022342109308476	0.830190299122522	0.0427769985974754	0.0044825178297132
cd8-positive t-lymphocytes/cytology	chemokines/metabolism	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cd8-positive t-lymphocytes/cytology	ctla-4 antigen/immunology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cd8-positive t-lymphocytes/cytology	gene expression regulation/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cd8-positive t-lymphocytes/cytology	melanoma/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cd8-positive t-lymphocytes/cytology	multigene family	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cd8-positive t-lymphocytes/cytology	myeloid cells/cytology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cd8-positive t-lymphocytes/cytology	receptors antigen t-cell/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cd8-positive t-lymphocytes/cytology	receptors cxcr3/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cd8-positive t-lymphocytes/cytology	receptors cxcr6/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cd8-positive t-lymphocytes/cytology	t-lymphocytes regulatory/cytology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
chemokines/metabolism	ctla-4 antigen/immunology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
chemokines/metabolism	gene expression regulation/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
chemokines/metabolism	melanoma/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
chemokines/metabolism	multigene family	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
chemokines/metabolism	myeloid cells/cytology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
chemokines/metabolism	receptors antigen t-cell/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
chemokines/metabolism	receptors cxcr3/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
chemokines/metabolism	receptors cxcr6/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
chemokines/metabolism	t-lymphocytes regulatory/cytology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
ctla-4 antigen/immunology	gene expression regulation/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
ctla-4 antigen/immunology	melanoma/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
ctla-4 antigen/immunology	multigene family	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
ctla-4 antigen/immunology	myeloid cells/cytology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
ctla-4 antigen/immunology	receptors antigen t-cell/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
ctla-4 antigen/immunology	receptors cxcr3/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
ctla-4 antigen/immunology	receptors cxcr6/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
ctla-4 antigen/immunology	t-lymphocytes regulatory/cytology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
gene expression regulation/genetics	melanoma/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
gene expression regulation/genetics	multigene family	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
gene expression regulation/genetics	myeloid cells/cytology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
gene expression regulation/genetics	receptors antigen t-cell/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
gene expression regulation/genetics	receptors cxcr3/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
gene expression regulation/genetics	receptors cxcr6/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
gene expression regulation/genetics	t-lymphocytes regulatory/cytology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
melanoma/genetics	multigene family	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
melanoma/genetics	myeloid cells/cytology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
melanoma/genetics	receptors antigen t-cell/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
melanoma/genetics	receptors cxcr3/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
melanoma/genetics	receptors cxcr6/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
melanoma/genetics	t-lymphocytes regulatory/cytology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
multigene family	myeloid cells/cytology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
multigene family	receptors antigen t-cell/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
multigene family	receptors cxcr3/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
multigene family	receptors cxcr6/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
multigene family	t-lymphocytes regulatory/cytology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
myeloid cells/cytology	receptors antigen t-cell/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
myeloid cells/cytology	receptors cxcr3/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
myeloid cells/cytology	receptors cxcr6/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
myeloid cells/cytology	t-lymphocytes regulatory/cytology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
receptors antigen t-cell/genetics	receptors cxcr3/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
receptors antigen t-cell/genetics	receptors cxcr6/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
receptors antigen t-cell/genetics	t-lymphocytes regulatory/cytology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
receptors cxcr3/genetics	receptors cxcr6/genetics	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
receptors cxcr3/genetics	t-lymphocytes regulatory/cytology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
receptors cxcr6/genetics	t-lymphocytes regulatory/cytology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
immunologic memory/drug effects	interferon-gamma/metabolism	0	1	2.57265308056809e-07	0.830190299122522	0.010752688172043	1.66393968736404e-06
immunologic memory/drug effects	piperidines/therapeutic use	0	1	3.67543332718823e-05	0.830190299122522	0.021505376344086	0.0001340865542691
immunologic memory/drug effects	pyrimidines/therapeutic use	0	1	3.67543332718823e-05	0.830190299122522	0.021505376344086	0.0001340865542691
interferon-gamma/metabolism	piperidines/therapeutic use	0	1	3.67543332718823e-05	0.830190299122522	0.021505376344086	0.0001340865542691
interferon-gamma/metabolism	pyrimidines/therapeutic use	0	1	3.67543332718823e-05	0.830190299122522	0.021505376344086	0.0001340865542691
piperidines/therapeutic use	protein kinase inhibitors/therapeutic use	0	1	1.4077731091966e-08	0.830190299122522	0.021505376344086	9.94826330498929e-08
piperidines/therapeutic use	pyrimidines/therapeutic use	0	2	4.5445092133888894e-11	0.584635003932401	0.0002337540906965	4.9832894133023e-10
pyrimidines/therapeutic use	protein kinase inhibitors/therapeutic use	0	1	1.4077731091966e-08	0.830190299122522	0.021505376344086	9.94826330498929e-08
cd8-positive t-lymphocytes/immunology	cytotoxicity immunologic	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cd8-positive t-lymphocytes/immunology	drug-related side effects and adverse reactions/prevention & control	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cd8-positive t-lymphocytes/immunology	growth inhibitors/therapeutic use	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cd8-positive t-lymphocytes/immunology	immune checkpoint inhibitors/therapeutic use	0	1	0.0032890445713762	0.830190299122522	0.021505376344086	0.0063197351885054
cd8-positive t-lymphocytes/immunology	lymphocytes tumor-infiltrating/immunology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cd8-positive t-lymphocytes/immunology	MTOR	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cd8-positive t-lymphocytes/immunology	phosphatidylinositol 3-kinases/metabolism	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cd8-positive t-lymphocytes/immunology	sirolimus/therapeutic use	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cytotoxicity immunologic	drug-related side effects and adverse reactions/prevention & control	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cytotoxicity immunologic	growth inhibitors/therapeutic use	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cytotoxicity immunologic	immune checkpoint inhibitors/therapeutic use	0	1	0.0032890445713762	0.830190299122522	0.021505376344086	0.0063197351885054
cytotoxicity immunologic	lymphocytes tumor-infiltrating/immunology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cytotoxicity immunologic	MTOR	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cytotoxicity immunologic	phosphatidylinositol 3-kinases/metabolism	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
cytotoxicity immunologic	sirolimus/therapeutic use	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
drug-related side effects and adverse reactions/prevention & control	growth inhibitors/therapeutic use	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
drug-related side effects and adverse reactions/prevention & control	immune checkpoint inhibitors/therapeutic use	0	1	0.0032890445713762	0.830190299122522	0.021505376344086	0.0063197351885054
drug-related side effects and adverse reactions/prevention & control	lymphocytes tumor-infiltrating/immunology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
drug-related side effects and adverse reactions/prevention & control	MTOR	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
drug-related side effects and adverse reactions/prevention & control	phosphatidylinositol 3-kinases/metabolism	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
drug-related side effects and adverse reactions/prevention & control	sirolimus/therapeutic use	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
growth inhibitors/therapeutic use	immune checkpoint inhibitors/therapeutic use	0	1	0.0032890445713762	0.830190299122522	0.021505376344086	0.0063197351885054
growth inhibitors/therapeutic use	lymphocytes tumor-infiltrating/immunology	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
growth inhibitors/therapeutic use	MTOR	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
growth inhibitors/therapeutic use	phosphatidylinositol 3-kinases/metabolism	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
growth inhibitors/therapeutic use	sirolimus/therapeutic use	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
immune checkpoint inhibitors/therapeutic use	lymphocytes tumor-infiltrating/immunology	0	1	0.0032890445713762	0.830190299122522	0.021505376344086	0.0063197351885054
immune checkpoint inhibitors/therapeutic use	MTOR	0	1	0.0032890445713762	0.830190299122522	0.021505376344086	0.0063197351885054
immune checkpoint inhibitors/therapeutic use	phosphatidylinositol 3-kinases/metabolism	0	1	0.0032890445713762	0.830190299122522	0.021505376344086	0.0063197351885054
immune checkpoint inhibitors/therapeutic use	sirolimus/therapeutic use	0	1	0.0032890445713762	0.830190299122522	0.021505376344086	0.0063197351885054
lymphocytes tumor-infiltrating/immunology	MTOR	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
lymphocytes tumor-infiltrating/immunology	phosphatidylinositol 3-kinases/metabolism	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
lymphocytes tumor-infiltrating/immunology	sirolimus/therapeutic use	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
MTOR	phosphatidylinositol 3-kinases/metabolism	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
MTOR	sirolimus/therapeutic use	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
phosphatidylinositol 3-kinases/metabolism	sirolimus/therapeutic use	0	1	8.68426534594846e-06	0.830190299122522	0.010752688172043	3.54050817950207e-05
colitis	diarrhea	0	2	0.0	0.584635003932401	0.0014025245441795	0.0
colitis	ligands	0	1	9.620737539961509e-11	0.830190299122522	0.043010752688172	1.0197981792359201e-09
colitis	neoplasms	0	1	2.73582738142819e-05	0.830190299122522	0.163750819851802	0.0001015556156374
colitis	pneumonia	0	1	9.620737539961509e-11	0.830190299122522	0.043010752688172	1.0197981792359201e-09
colitis	recurrence	0	1	1.2526646386845599e-12	0.830190299122522	0.043010752688172	1.8672532270391797e-11
diarrhea	neoplasms	0	1	1.04816155754861e-11	0.830190299122522	0.0846189808321645	1.48140166800204e-10
diarrhea	recurrence	0	1	0.0	0.830190299122522	0.021505376344086	0.0
ligands	pneumonia	0	1	0.0	0.830190299122522	0.010752688172043	0.0
neoplasms	LTF	0	1	7.771561172376101e-16	0.830190299122522	0.043010752688172	1.66608300189816e-14
neoplasms	recurrence	0	1	7.771561172376101e-16	0.830190299122522	0.043010752688172	1.66608300189816e-14
recurrence	antineoplastic agents/adverse effects	1	1	0.0001984421546249	0.8192464059779487	0.0212765957446808	0.0004762611710998
recurrence	intestinal mucosa/chemistry	1	1	0.0001984421546249	0.8192464059779487	0.0212765957446808	0.0004762611710998
recurrence	leukemia lymphocytic chronic b-cell/drug therapy	1	1	0.0001984421546249	0.8192464059779487	0.0212765957446808	0.0004762611710998
recurrence	class i phosphatidylinositol 3-kinases/antagonists & inhibitors	1	1	0.0001984421546249	0.8192464059779487	0.0212765957446808	0.0004762611710998
recurrence	purines/adverse effects	1	1	0.0001984421546249	0.8192464059779487	0.0212765957446808	0.0004762611710998
recurrence	colon/chemistry	1	1	0.0001984421546249	0.8192464059779487	0.0212765957446808	0.0004762611710998
recurrence	lymphocytosis/chemically induced	1	1	0.0001984421546249	0.8192464059779487	0.0212765957446808	0.0004762611710998
recurrence	protein kinase inhibitors/adverse effects	1	1	0.0001984421546249	0.8192464059779487	0.0212765957446808	0.0004762611710998
recurrence	apoptosis/drug effects	1	1	0.0001984421546249	0.8192464059779487	0.0212765957446808	0.0004762611710998
recurrence	quinazolinones/adverse effects	1	1	0.0001984421546249	0.8192464059779487	0.0212765957446808	0.0004762611710998
recurrence	lymphoma non-hodgkin/drug therapy	1	1	0.0001984421546249	0.8192464059779487	0.0212765957446808	0.0004762611710998
recurrence	PIK3CD	1	1	0.0001984421546249	0.8192464059779487	0.0212765957446808	0.0004762611710998
colitis collagenous/drug therapy	skin neoplasms/complications	0	1	0.0	0.830190299122522	0.010752688172043	0.0
colitis microscopic/chemically induced	inflammatory bowel diseases/complications	0	1	0.0	0.830190299122522	0.0427769985974754	0.0
nivolumab/adverse effects	colitis/chemically induced	0	10	0.0041246524905659	0.0002278681042509	0.351518422440415	0.0077230980883216
nivolumab/adverse effects	disease susceptibility	0	1	8.27983542073252e-06	0.830190299122522	0.129032258064516	3.54050817950207e-05
nivolumab/adverse effects	drug-related side effects and adverse reactions/diagnosis	0	1	0.0003058560984983	0.830190299122522	0.129032258064516	0.0007520276236272
nivolumab/adverse effects	ipilimumab/adverse effects	0	7	0.0	0.010308700389748	2.70981274267652e-06	0.0
nivolumab/adverse effects	lung neoplasms/drug therapy	0	1	0.0036027646835737	0.830190299122522	0.242636746143057	0.0067591691408641
nivolumab/adverse effects	oropharyngeal neoplasms/drug therapy	0	1	8.27983542073252e-06	0.830190299122522	0.129032258064516	3.54050817950207e-05
nivolumab/adverse effects	postoperative complications	0	1	8.27983542073252e-06	0.830190299122522	0.129032258064516	3.54050817950207e-05
nivolumab/adverse effects	prednisolone/therapeutic use	0	1	8.27983542073252e-06	0.830190299122522	0.129032258064516	3.54050817950207e-05
nivolumab/adverse effects	protein kinase inhibitors/therapeutic use	0	1	0.000872653019809	0.830190299122522	0.129032258064516	0.0020084704002361
colitis ulcerative/drug therapy	crohn disease/drug therapy	0	1	0.0	0.830190299122522	0.021505376344086	0.0
colitis ulcerative/drug therapy	interleukin-12/antagonists & inhibitors	0	1	0.0	0.830190299122522	0.021505376344086	0.0
colitis ulcerative/drug therapy	interleukin-23/antagonists & inhibitors	0	1	0.0	0.830190299122522	0.021505376344086	0.0
colitis ulcerative/drug therapy	ustekinumab/therapeutic use	0	1	0.0	0.830190299122522	0.021505376344086	0.0
interleukin-12/antagonists & inhibitors	interleukin-23/antagonists & inhibitors	0	1	0.0	0.830190299122522	0.010752688172043	0.0
interleukin-12/antagonists & inhibitors	ustekinumab/therapeutic use	0	1	0.0	0.830190299122522	0.010752688172043	0.0
interleukin-23/antagonists & inhibitors	ustekinumab/therapeutic use	0	1	0.0	0.830190299122522	0.010752688172043	0.0
colitis ulcerative/physiopathology	crohn disease/physiopathology	0	1	0.0	0.830190299122522	0.010752688172043	0.0
colitis/chemically induced	ipilimumab/adverse effects	0	9	0.0007075612536729	0.0008903144156418	0.0589207356081562	0.0016423684574307
ipilimumab/adverse effects	drug-related side effects and adverse reactions/diagnosis	0	1	2.16563430855965e-05	0.830190299122522	0.0967741935483871	8.14996106653217e-05
ipilimumab/adverse effects	protein kinase inhibitors/therapeutic use	0	1	8.84097061502054e-05	0.830190299122522	0.0967741935483871	0.0002777578837603
disease susceptibility	postoperative complications	0	1	0.0	0.830190299122522	0.010752688172043	0.0
diarrhea/therapy	neoplasms/therapy	0	1	0.0	0.830190299122522	0.010752688172043	0.0
colitis/therapy	immunologic factors	0	1	0.0	0.830190299122522	0.021505376344086	0.0
colon/diagnostic imaging	drug resistance/immunology	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
colon/diagnostic imaging	glucocorticoids/pharmacology	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
colon/diagnostic imaging	immunosuppressive agents/pharmacology	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
colon/diagnostic imaging	intestinal mucosa/diagnostic imaging	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
colon/diagnostic imaging	melanoma/drug therapy	0	1	0.0001660054582111	0.830190299122522	0.053763440860215	0.0004664777824253
colon/diagnostic imaging	mucositis/chemically induced	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
drug resistance/immunology	glucocorticoids/pharmacology	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
drug resistance/immunology	immunosuppressive agents/pharmacology	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
drug resistance/immunology	intestinal mucosa/diagnostic imaging	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
drug resistance/immunology	melanoma/drug therapy	0	1	0.0001660054582111	0.830190299122522	0.053763440860215	0.0004664777824253
drug resistance/immunology	mucositis/chemically induced	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
glucocorticoids/pharmacology	immunosuppressive agents/pharmacology	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
glucocorticoids/pharmacology	intestinal mucosa/diagnostic imaging	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
glucocorticoids/pharmacology	melanoma/drug therapy	0	1	0.0001660054582111	0.830190299122522	0.053763440860215	0.0004664777824253
glucocorticoids/pharmacology	mucositis/chemically induced	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
immunosuppressive agents/pharmacology	intestinal mucosa/diagnostic imaging	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
immunosuppressive agents/pharmacology	melanoma/drug therapy	0	1	0.0001660054582111	0.830190299122522	0.053763440860215	0.0004664777824253
immunosuppressive agents/pharmacology	mucositis/chemically induced	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
intestinal mucosa/diagnostic imaging	melanoma/drug therapy	0	1	0.0001660054582111	0.830190299122522	0.053763440860215	0.0004664777824253
intestinal mucosa/diagnostic imaging	mucositis/chemically induced	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
melanoma/drug therapy	mucositis/chemically induced	0	1	0.0001660054582111	0.830190299122522	0.053763440860215	0.0004664777824253
colon/immunology	intestinal mucosa/immunology	0	1	0.0	0.830190299122522	0.021505376344086	0.0
colon/immunology	t-lymphocyte subsets/immunology	0	1	0.0	0.830190299122522	0.021505376344086	0.0
CXCL10	CXCL9	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
CXCL10	dermatitis	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
CXCL10	psoriasis	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
CXCL10	rna	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
CXCL10	TCIM	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
CXCL9	dermatitis	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
CXCL9	psoriasis	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
CXCL9	rna	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
CXCL9	TCIM	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
dermatitis	psoriasis	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
dermatitis	rna	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
dermatitis	TCIM	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
psoriasis	rna	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
psoriasis	TCIM	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
rna	TCIM	0	1	1.69131375571396e-11	0.830190299122522	0.010752688172043	1.90948322242736e-10
feces	steroids/therapeutic use	0	1	0.0	0.830190299122522	0.021505376344086	0.0
steroids/therapeutic use	lung neoplasms	0	1	0.0	0.830190299122522	0.021505376344086	0.0
esophagitis	ulcer/chemically induced	0	1	0.0	0.830190299122522	0.010752688172043	0.0
prednisolone/therapeutic use	lung neoplasms/drug therapy	0	1	0.0	0.830190299122522	0.021505376344086	0.0
antineoplastic agents/adverse effects	intestinal mucosa/chemistry	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
antineoplastic agents/adverse effects	leukemia lymphocytic chronic b-cell/drug therapy	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
antineoplastic agents/adverse effects	class i phosphatidylinositol 3-kinases/antagonists & inhibitors	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
antineoplastic agents/adverse effects	purines/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
antineoplastic agents/adverse effects	colon/chemistry	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
antineoplastic agents/adverse effects	lymphocytosis/chemically induced	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
antineoplastic agents/adverse effects	protein kinase inhibitors/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
antineoplastic agents/adverse effects	apoptosis/drug effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
antineoplastic agents/adverse effects	quinazolinones/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
antineoplastic agents/adverse effects	lymphoma non-hodgkin/drug therapy	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
antineoplastic agents/adverse effects	PIK3CD	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
intestinal mucosa/chemistry	leukemia lymphocytic chronic b-cell/drug therapy	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
intestinal mucosa/chemistry	class i phosphatidylinositol 3-kinases/antagonists & inhibitors	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
intestinal mucosa/chemistry	purines/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
intestinal mucosa/chemistry	colon/chemistry	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
intestinal mucosa/chemistry	lymphocytosis/chemically induced	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
intestinal mucosa/chemistry	protein kinase inhibitors/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
intestinal mucosa/chemistry	apoptosis/drug effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
intestinal mucosa/chemistry	quinazolinones/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
intestinal mucosa/chemistry	lymphoma non-hodgkin/drug therapy	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
intestinal mucosa/chemistry	PIK3CD	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
leukemia lymphocytic chronic b-cell/drug therapy	class i phosphatidylinositol 3-kinases/antagonists & inhibitors	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
leukemia lymphocytic chronic b-cell/drug therapy	purines/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
leukemia lymphocytic chronic b-cell/drug therapy	colon/chemistry	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
leukemia lymphocytic chronic b-cell/drug therapy	lymphocytosis/chemically induced	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
leukemia lymphocytic chronic b-cell/drug therapy	protein kinase inhibitors/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
leukemia lymphocytic chronic b-cell/drug therapy	apoptosis/drug effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
leukemia lymphocytic chronic b-cell/drug therapy	quinazolinones/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
leukemia lymphocytic chronic b-cell/drug therapy	lymphoma non-hodgkin/drug therapy	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
leukemia lymphocytic chronic b-cell/drug therapy	PIK3CD	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	purines/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	colon/chemistry	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	lymphocytosis/chemically induced	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	protein kinase inhibitors/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	apoptosis/drug effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	quinazolinones/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	lymphoma non-hodgkin/drug therapy	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	PIK3CD	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
purines/adverse effects	colon/chemistry	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
purines/adverse effects	lymphocytosis/chemically induced	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
purines/adverse effects	protein kinase inhibitors/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
purines/adverse effects	apoptosis/drug effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
purines/adverse effects	quinazolinones/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
purines/adverse effects	lymphoma non-hodgkin/drug therapy	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
purines/adverse effects	PIK3CD	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
colon/chemistry	lymphocytosis/chemically induced	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
colon/chemistry	protein kinase inhibitors/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
colon/chemistry	apoptosis/drug effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
colon/chemistry	quinazolinones/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
colon/chemistry	lymphoma non-hodgkin/drug therapy	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
colon/chemistry	PIK3CD	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
lymphocytosis/chemically induced	protein kinase inhibitors/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
lymphocytosis/chemically induced	apoptosis/drug effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
lymphocytosis/chemically induced	quinazolinones/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
lymphocytosis/chemically induced	lymphoma non-hodgkin/drug therapy	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
lymphocytosis/chemically induced	PIK3CD	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
protein kinase inhibitors/adverse effects	apoptosis/drug effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
protein kinase inhibitors/adverse effects	quinazolinones/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
protein kinase inhibitors/adverse effects	lymphoma non-hodgkin/drug therapy	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
protein kinase inhibitors/adverse effects	PIK3CD	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
apoptosis/drug effects	quinazolinones/adverse effects	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
apoptosis/drug effects	lymphoma non-hodgkin/drug therapy	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
apoptosis/drug effects	PIK3CD	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
quinazolinones/adverse effects	lymphoma non-hodgkin/drug therapy	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
quinazolinones/adverse effects	PIK3CD	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
lymphoma non-hodgkin/drug therapy	PIK3CD	1	1	1.8160047809523405e-05	0.8192464059779487	0.0106382978723404	6.398358813718091e-05
